

1 **Analysis of respiratory and systemic immune responses in COVID-19 reveals** 2 **mechanisms of disease pathogenesis**

3 Peter A. Szabo^{1,2*}, Pranay Dogra^{1,2*}, Joshua I. Gray^{1,2*}, Steven B. Wells^{3*}, Thomas J.
4 Connors⁵, Stuart P. Weisberg⁷, Izabela Krupka³, Rei Matsumoto^{1,4}, Maya M.L. Poon^{1,10},
5 Emma Idzikowski⁵, Sinead E. Morris⁷, Chloé Pasin⁷, Andrew J. Yates⁷, Amy Ku⁷, Michael
6 Chait⁷, Julia Davis-Porada¹⁰, Jing Zhou⁹, Matthew Steinle⁹, Sean Mackay⁹, Anjali Saqi⁷,
7 Matthew Baldwin⁶, Peter A. Sims^{3,8} and Donna L. Farber^{1,2,4}

8
9 ¹Columbia Center for Translational Immunology, Columbia University Irving Medical
10 Center, New York, NY 10032

11 ²Department of Microbiology and Immunology, Columbia University Irving Medical
12 Center, New York, NY 10032

13 ³Department of Systems Biology, Columbia University Irving Medical Center, New York,
14 NY 10032

15 ⁴Department of Surgery, Columbia University Irving Medical Center, New York, NY 10032

16 ⁵Department of Pediatrics, Columbia University Irving Medical Center, New York, NY
17 10032

18 ⁶Department of Medicine, Columbia University Irving Medical Center, New York, NY
19 10032

20 ⁷Department of Pathology and Cell Biology, Columbia University Irving Medical Center,
21 New York, NY 10032

22 ⁸Department of Biochemistry and Molecular Biophysics, Columbia University Irving
23 Medical Center, New York, NY 10032

24 ⁹IsoPlexis Corporation, Branford, CT 06405

25 ¹⁰Medical Scientist Training Program, Columbia University
26

27 *Equal Contribution (Columbia- COVID-19 airway immunity team)
28

29 **SUMMARY**

30 Immune responses to respiratory viruses like SARS-CoV-2 originate and function in the lung,
31 yet assessments of human immunity are often limited to blood. Here, we conducted longitudinal,
32 high-dimensional profiling of paired airway and blood samples from patients with severe
33 COVID-19, revealing immune processes in the respiratory tract linked to disease pathogenesis.
34 Survival from severe disease was associated with increased CD4⁺T cells and decreased
35 monocyte/macrophage frequencies in the airway, but not in blood. Airway T cells and
36 macrophages exhibited tissue-resident phenotypes and activation signatures, including high level
37 expression and secretion of monocyte chemoattractants CCL2 and CCL3 by airway
38 macrophages. By contrast, monocytes in blood expressed the CCL2-receptor CCR2 and aberrant
39 CD163⁺ and immature phenotypes. Extensive accumulation of CD163⁺monocyte/macrophages
40 within alveolar spaces in COVID-19 lung autopsies suggested recruitment from circulation. Our
41 findings provide evidence that COVID-19 pathogenesis is driven by respiratory immunity, and
42 rationale for site-specific treatment and prevention strategies.

43
44 **Key Words:** COVID-19, lung immunity, ARDS, tissue resident memory T cells, macrophages
45

1 INTRODUCTION

2 The novel respiratory virus SARS-CoV-2 has resulted in devastating impacts to the
3 world's population, both as a result of morbidity and mortality caused by COVID-19, as well as
4 the life-altering measures implemented to mitigate spread. While the majority of infected
5 individuals (>90%) develop a self-limiting disease and recover, approximately 5-10% of
6 individuals develop severe respiratory disease marked by lung infiltrates and reduced oxygen
7 saturation, which can progress to acute respiratory distress syndrome (ARDS), multi-organ
8 failure, and death (Wu and McGoogan, 2020). Risk factors for severe COVID-19 include older
9 age and co-morbidities like obesity and diabetes, although younger and previously healthy
10 individuals can also be susceptible (Cummings et al., 2020; Davies et al., 2020). For individuals
11 who recover from self-limiting illness, the immune system acts in a coordinated fashion to clear
12 the virus and establish virus-specific immunity (Moderbacher et al., 2020). However, the role of
13 the immune response in the pathogenesis of severe COVID-19 remains unclear, and
14 understanding this phenomenon is urgently required to develop new treatment and prevention
15 strategies.

16 A key aspect of the immune response to respiratory virus infection is the activation and
17 mobilization of immune cells to the lung for viral clearance. Innate immune responses are
18 initiated within infected lung epithelial cells and local immune cells, including tissue resident
19 alveolar macrophages and infiltrating monocytes and granulocytes (Yoo et al., 2013). The initial
20 production of pro-inflammatory cytokines in the lung can precipitate cytokine storms in severe
21 respiratory infections (Tejaro et al., 2011b). Adaptive immune responses are also mobilized in
22 the lung; antigen-loaded dendritic cells migrate from the infected lung to the draining lymph
23 node where they prime CD4⁺ and CD8⁺T cells. The resultant effector T cells traffic to the lung to

1 mediate clearance of infected cells *in situ* (Yoo et al., 2013). A proportion of these lung effector
2 T cells develop into tissue resident memory T cells (TRM), which are retained in the lung and
3 can mediate rapid protective responses upon viral challenge in mouse models (Teijaro et al.,
4 2011a; Turner et al., 2014; Turner and Farber, 2014; Wu et al., 2014). TRM in mice and humans
5 are phenotypically and transcriptionally distinct from circulating effector-memory (TEM) cells
6 (Kumar et al., 2017; Mackay et al., 2016; Masopust and Soerens, 2019). In adult lungs, TRM are
7 the predominant T cell subset and persist in stable frequencies throughout life (Kumar et al.,
8 2018), suggesting a crucial role in protection to respiratory pathogens. Moreover, CD4⁺TRM-
9 like cells in the airway are required for protection against SARS-CoV-1 in mice (Zhao et al.,
10 2016). At present, we lack information on the role of resident immune cells, including alveolar
11 macrophages and lung TRM in protection against SARS-CoV-2 infection, and their function in
12 the pathogenesis of severe COVID-19.

13 Studies of the immune response to SARS-CoV-2 have examined innate and adaptive
14 immune cells, as well as soluble mediators in blood and plasma of infected individuals, revealing
15 elevated levels of pro-inflammatory cytokines (Hadjadj et al., 2020; Laing et al., 2020) and
16 robust virus-specific adaptive immune responses. Virus-specific CD4⁺ and CD8⁺T cells are
17 found in most infected individuals with varying disease severities and persist following recovery
18 (Grifoni et al., 2020; Thieme et al., 2020; Weiskopf et al., 2020). Antibodies specific for
19 different viral proteins, including anti-Spike (S) protein-specific neutralizing antibodies (Long et
20 al., 2020; Ni et al., 2020), also persist after resolution. How these systemic immune responses
21 relate to innate and adaptive immunity in the respiratory tract is unclear and difficult to assess.

22 Here, we present in-depth, high-dimensional profiling of innate and adaptive immune
23 cells and their functional responses in paired airway and blood samples obtained longitudinally

1 from 15 patients with severe COVID-19, along with control airway and blood samples. We
2 identified robust innate and adaptive immune responses in the airway, which were distinct from
3 blood in cellular composition, function and transcriptional profile. Notably, increased
4 frequencies CD4⁺T cells and decreased frequencies monocytes/macrophages in airways were
5 associated with survival and younger age, suggesting key roles for these cells at the infection
6 site. COVID-19 airways contained activated TRM, high frequencies of inflammatory tissue
7 monocytes/macrophages, and supranormal levels of the monocyte chemoattractant cytokines
8 CCL2, CCL3, and CCL4 — all lacking in blood, which contained predominant populations of
9 immature monocytes. Excessive macrophage/monocyte content in COVID-19 lung autopsies
10 compared to control lungs provide evidence for dynamic monocyte recruitment to the respiratory
11 tract. Our results reveal compartmentalization of innate and adaptive immune responses in the
12 respiratory tract of COVID-19, which drives peripheral immune cell infiltration and disease
13 pathogenesis.

14

1 **RESULTS**

2 **Obtaining paired airway and blood samples from severe COVID-19 patients**

3 During the height of the pandemic in New York City, between April and June 2020, we
4 enrolled patients from adult and pediatric intensive care units at New York Presbyterian hospital
5 with severe COVID-19 (confirmed by positive SARS-CoV-2 PCR). Enrolled patients required
6 mechanical ventilator support enabling us to obtain paired airway and blood samples
7 longitudinally for up to 10 days during their hospitalization (average 6-7 sample days per
8 patient). Sampling for each patient began within 24-36 hours of intubation. Patients represented a
9 broad age range (14-84 yrs) and 8/15 (53%) died during enrollment or soon after (Table S1).
10 Enrolled COVID-19 patients exhibited similar clinical severity measures regardless of outcome;
11 the extent of ARDS, inflammation, neutrophil levels and comorbidities were similar between
12 deceased patients and those who survived, while median age differed significantly (72yrs,
13 deceased; 39yrs, survived). All patients developed robust SARS-CoV-2-specific neutralizing
14 antibodies as measured in plasma (Weisberg et al., 2020).

15 Airway samples were obtained using a saline wash of the endotracheal tube performed
16 daily as part of clinical care, which we have previously shown contain respiratory immune cell
17 populations (Connors et al., 2018; Connors et al., 2016). A total of 141 paired blood and airway
18 cell preparations were analyzed by high-dimensional spectral flow cytometry and successive
19 samples from four patients were profiled by scRNAseq (Figure 1A, Table S2, S3). Airway
20 supernatants and blood plasma from early and late time points were also assayed for cytokines
21 and chemokines (Figure 1A, Table S2).

22

23 **Distinct immune cell composition in airway and blood of COVID-19 patients**

1 Mononuclear cells from paired airway and blood samples were isolated by centrifugation
2 through ficoll (see methods), stained using a 34 marker panel containing antibodies specific for
3 major lineage determinants and markers for differentiation, tissue residence, activation, and
4 function (see methods), and analyzed by spectral flow cytometry (gating strategy for
5 mononuclear cells shown in Figure S1). Principal component analysis (PCA) of mean marker
6 expression for each sample showed distinct clustering of airway and blood samples by site, but
7 not by outcome or by patient (Figure 1B, Table S4). Computational analysis of flow cytometry
8 data visualized by uniform manifold approximation and projection (UMAP) embedding (see
9 methods) showed distinct separation of the major lineages into monocytes/macrophages, CD4⁺T
10 cells, CD8⁺T cells, B cells, and innate lymphoid cells (predominantly NK cells) for all samples
11 (Figure 1C, Figure S2A). Compiled data for each timepoint revealed distinct immune cell
12 composition in airway compared to blood (Figure 1D). Airway samples had predominant
13 frequencies of monocytes/macrophages (40-90%), lower T cell frequencies, and very low-to-
14 negligible frequencies of B cells and ILCs, while blood contained higher lymphocyte frequencies
15 with monocytes comprising ~50% of all non-neutrophil leukocytes (Figure 1D). Similar immune
16 cell compositions were confirmed by scRNAseq analysis of airway and blood from four
17 individuals (Figure S2B). These results show distinct immune cell profiles in airway compared to
18 blood across all patients and timepoints analyzed.

19 We investigated whether the airway or blood immune cell composition differentiated
20 between patients or correlated with overall survival. Hierarchical clustering of aggregated
21 samples from each individual revealed two major patterns of immune cell composition in the
22 airways; one pattern showing a predominance of monocytes/macrophages, while the second
23 pattern had higher frequencies of CD4⁺T cells, B cells, and ILCs compared to the first (Figure 1E

1 left). However, neither pattern significantly correlated to outcome as patients who survived or
2 succumbed were represented in both groups (Figure 1E, left). Hierarchical clustering of blood
3 immune cell data revealed multiple clusters with different numbers of patients in each with no
4 clear distinction in patterns or by patient outcome (Figure 1E, right). The longitudinal profiles of
5 immune cell composition for individual patient samples also showed distinct composition in
6 airways, which did not correspond to blood either in frequency or in changes over time (Figure
7 1F, Figure S3A). However, examination of specific lineages showed significant associations with
8 outcome and correlation with age. Notably, there was a significant decrease in frequencies of
9 airway monocytes/macrophages and an increase in airway CD4⁺T cells in patients who survived
10 the disease versus those who succumbed (Figure 1G, left, Figure S3B), while the frequency of
11 the corresponding blood immune cell subsets did not significantly differ between patients based
12 on outcome, nor did they correlate with age (Figure 1G, right, Figure S3B). Accordingly,
13 clustering the longitudinal patterns of cell type frequencies using K-means further suggests that
14 airway immune cell trajectories are a better indicator of clinical outcome than their blood
15 counterparts (Figure S3C). Together, these results show that airways exhibit an immune cell
16 composition distinct from blood, and that the dynamics of airway T cells and
17 monocyte/macrophages are significantly associated with outcome, suggesting key roles for these
18 cell types in disease pathogenesis.

19

20 **Tissue resident memory T cells are the major T cell subset in airways**

21 The subset composition and transcriptional profile of airway T cells in comparison to
22 those in blood was further examined through high-dimensional, single cell approaches. Multiple
23 markers of T cell differentiation were used to distinguish naïve and memory populations

1 (CD45RA, CCR7, CD95, CD27), activation (HLA-DR, PD-1), functional subsets (FOXP3/CD25
2 for Tregs, CXCR5/PD-1 for Tfh-like, TCRGD for $\gamma\delta$ T cells), specific states of senescence or
3 terminal differentiation (CD57, KLRG1), and tissue residence (CD69, CD103). We used UMAP
4 embedding to visualize expression of these multiple markers by airway and blood T cells,
5 showing increased expression of CD69, CD103, PD-1, and HLA-DR in the airways and
6 increased CCR7, CD45RA, and CD127 expression in the blood (Figure S4A and S4B).
7 Phenograph clustering based on marker expression by CD4⁺ and CD8⁺T cells yielded 27
8 clusters, which were coalesced into 15 clusters denoting biological subsets or
9 functional/activation states in airway and blood (Figure 2A, 2B).

10 There were significant qualitative and quantitative differences in T cell subset
11 composition and activation state between airway and blood. In particular, airway contained CD4⁺
12 and CD8⁺TRM cells (CD69⁺CD103^{+/-}) along with activated TRM subsets expressing elevated
13 levels of HLA-DR and PD-1, and reduced levels of CD127 compared to non-activated TRM
14 (Figure 2A, 2B). TRM cells, regardless of activation state, were largely confined to the airways
15 and not significantly present in blood (Figure 2B, 2C), consistent with virus-responding T cells
16 located at the site of infection. Innate-like $\gamma\delta$ cells were also present in higher frequencies in
17 airways compared to blood (Figure 2C). Circulating TEM cells (CD69⁻CD103⁻) were present in
18 both sites, with non-activated CD8⁺TEM enriched in the blood (Figure 2B, 2C). Blood also
19 contained higher frequencies of naïve CD4⁺ and CD8⁺T cells, CD4⁺TCM cells (Figure 2B, 2C).
20 Between patients, there was variability in the proportions of the major subsets represented; most
21 patients (9/13) had predominant CD8⁺TRM in airways, while 3/13 patients had higher
22 frequencies of CD4⁺TRM in airways (Figure 2D). Together, these analyses indicate that both
23 TRM and activated memory T cells (TRM and TEM) exhibit biased distribution in favor of the

1 airways and not blood, and that the subset composition and activation states of blood T cells does
2 reflect the dynamics in airways.

3 Consistent with the flow cytometry results, analysis of T cells by scRNA-seq revealed
4 distinct transcriptional profiles expressed by airway compared to blood T cells. TRM signature
5 genes *CXCR6* and *ITGA1* were uniquely expressed by airway T cells (Figure 2E, F, Table S5),
6 consistent with previous scRNA-seq analysis of human TRM cells in lung and other sites
7 (Snyder et al., 2019; Szabo et al., 2019). Naïve and TCM cells distinguished by *SELL* expression
8 were highly enriched in blood, while *CCL5* expression indicating TEM cells were found in both
9 sites (Figure 2F). Identification of the top differentially expressed genes between airway and
10 blood revealed that T cells from the airway exhibit a gene signature associated with TRM and
11 tissue T cells (Kumar et al., 2017; Szabo et al., 2019), including upregulated expression of
12 *CXCR6*, *ITGA1*, *PDCD1*, *LGALS*, *LAG3*, and *RBPJ* compared to blood T cells (Figure 2E, F,
13 Table S5). Airway T cells also showed upregulated expression of genes encoding key cytokines
14 and chemokines, including *IFNG*, *CCL2*, and *CCL4* (Figure 2E, F), consistent with an activated
15 and pro-inflammatory state. By contrast, blood T cells exhibited higher expression of genes
16 associated with quiescence (*TCF7*, *LEF1*) (Choi et al., 2015) and lymphoid homing (*SELL*)
17 compared to airway T cells (Figure 2E,F). These scRNA-seq results demonstrate
18 compartmentalization of activated TRM populations in the airway of severe COVID-19 in the
19 context of relatively quiescent blood T cells, suggesting that the protective T cell response is
20 targeted to the respiratory environment.

21

22 **Resident B cell subsets in the airway of COVID-19 patients**

1 The vast majority of B cells profiled in COVID-19 patients were from the blood;
2 however, there was a small but detectable population in the airways (Figure 1C, 1D). Comparing
3 B cell profiles by flow cytometry analysis revealed differential expression of key B cell markers
4 delineating specific B cells subsets in the airways and blood (Figure S5A, S5B). In particular,
5 airway B cells exhibited increased expression of CD69, a marker expressed by human tissue
6 resident B cells (Weisel et al., 2020), and activation markers CD86 and CD95 (Figure S5A,
7 S5B). Phenograph clustering further delineated subsets of activated and tissue-resident B cells
8 present in airways, while blood contained higher frequencies of CXCR5⁺ and naïve B cells
9 (Figure S5C-E). These results indicate compartmentalization of specific B cell subsets in airway,
10 providing further support for spatial segregation of adaptive immunity.

11

12 **Airway monocytes/macrophages exhibit activation and inflammatory profiles**

13 We applied similar high-dimensional flow cytometry and scRNA-seq analysis to the
14 monocyte/macrophage populations in paired airway and blood samples from COVID-19
15 patients. Phenotypic profiling of airway and blood samples defined a major
16 monocyte/macrophage population (see Figure 1), which largely segregated by site (Figure 3A).
17 Expression of markers HLA-DR, CD11c, and CD16 distinguished airway from blood
18 monocyte/macrophages, while those in blood expressed higher levels of CD14 and CD163
19 (Figure 3A, B). There was no difference in the relative expression of CD64 and CD86 between
20 airway and blood monocyte/macrophages (Figure 3B). Phenograph clustering of
21 monocytes/macrophages identified 20 clusters, which were coalesced into 6 clusters classified by
22 activation (HLA-DR and CD86) and major monocyte subsets: classical, intermediate, and non-
23 classical (Kapellos et al., 2019) (Figure 3C). Non-classical monocytes/macrophages (both non-

1 activated and activated) and activated classical monocytes/macrophages were enriched in the
2 airway (Figure 3D, E). By contrast, classical and intermediate monocytes/macrophages without
3 activation markers were increased in the blood (Figure 3D, E). These data indicated increased
4 activation of monocyte/macrophage lineages in the airway compared to blood.

5 We further investigated the subset delineation, differentiation, and functional state of
6 monocyte/macrophages by scRNA-seq. Transcriptionally, airway monocyte/macrophages
7 exhibited certain shared and distinct gene expression patterns compared to blood counterparts,
8 which were consistent across individuals (Figure 4A, Table S6). There was comparable
9 expression of lineage-defining genes, including *CD14*, *FCGR3A* (CD16), *CD68*, and *CD163*, for
10 monocyte/macrophages in the airway and blood. However, several genes distinguished the two
11 sites, including airway-specific expression of tissue macrophage markers *MARCO* and *MRC2*
12 (*CD206*) (Bharat et al., 2016) and the integrin *ITGAV* (encoding the vitronectin receptor for
13 tissue matrix interactions), while blood counterparts expressed higher levels of transcripts for
14 chemokine and homing/egress receptors (*CX3CR1*, *CCR2*, *SELL*, *SIPR4*) (Figure 4A). For genes
15 associated with myeloid cell function, airway monocytes/macrophages expressed highly elevated
16 levels of transcripts for pro-inflammatory mediators compared to blood, including chemokines
17 for recruitment of monocyte/macrophages (*CCL2*, *CCL3*, *CCL4*), lymphocytes (*CCL18*, *CCL20*,
18 *CCL23*), and neutrophils (*CXCL3*, *CXCL5*), complement components (*C3*, *CIQB*, *CIQC*), and
19 matrix metalloproteinases (*MMP9*, *MMP14*) implicated in tissue damage in ARDS (Hendrix and
20 Kheradmand, 2017) (Figure 4A). Together, these results demonstrate distinct tissue and
21 functional profiles of airway monocyte/macrophages compared to those in the blood.
22 Importantly, airway monocytes/macrophages persist in a highly inflammatory state with elevated

1 expression of chemotactic mediators, suggesting potential roles for lung macrophages in
2 recruiting immune cells to the lung in severe COVID-19.

3 Interferon (IFN)-regulated genes are associated with innate anti-viral immunity and may
4 be dysregulated in COVID-19 (Hadjadj et al., 2020). Accordingly, we found negligible
5 expression of genes encoding Type I, Type II, and Type III IFNs from monocyte/macrophages
6 (Figure 4B) or epithelial cells (Figure S6), consistent with the lack of SARS-CoV-2 viral
7 sequences (see methods) in scRNA-seq data from 4 patients. However, transcripts associated
8 with multiple interferon-regulated gene families (i.e., ISG, IFI, IFIT, IRF, MX and OAS) were
9 detected in both the airway and blood monocyte/macrophages (Figure 4B), as well as airway
10 epithelial and T cells (Figure S6), suggesting a persisting anti-viral state in these cells. This
11 expression of IFN-regulated genes may be propagated by *IFNG* expressed by airway T cells
12 (Figure 2, S6). Together these results indicate that the principal innate immune function of
13 myeloid-derived cells in severe COVID-19 is production of pro-inflammatory mediators by
14 airway monocyte/macrophages.

15

16 **Compartmentalized production of cytokines and chemokines in airway and blood**

17 We further assessed inflammation in both sites by direct examination of cytokine and
18 chemokine content in airway supernatants and plasma samples from an early (day 1) and later
19 (days 3-7) timepoint for each patient (Table S2). We used a microfluidic chip multiplexed
20 secretome proteomic platform for assessment of soluble mediators from each site with high
21 sensitivity from small volumes (see methods)(Farhadian et al., 2020). Overall, we found major,
22 significant differences in the cytokine and chemokine protein content in the airway compared to
23 plasma, but no significant differences between the two timepoints within a site (Figure 5A,

1 Figure S7A,B). Analytes significantly elevated in airways compared to blood include
2 monocyte/macrophage chemoattractants MCP-1 (CCL2), MIP-1 α (CCL3), and MIP1 β (CCL4)
3 in all samples, as well as granzyme B, IL-7, and TNF- β associated with T cells and homeostasis
4 (Figure 5A, 5B, Figure S7B). By contrast, in the blood, MCP-1 (CCL2), MIP-1 α (CCL3),
5 granzyme B, TNF- β , and IL-7 were undetectable, while MIP-1 β (CCL4) was present at variable
6 levels across patients (Figure 5A, B). Both blood and airways contained low and/or variable
7 levels of molecules associated with T cell effector function (perforin, IFN- γ , IL-17, and IL-2),
8 additional innate cytokines (IL-6 and IL-8), and TGF- β , while none of the analytes measured
9 were uniquely expressed by blood and not found in airways (Figure 5A, 5B, Figure S7B).
10 Together, these results show compartmentalized production of pro-inflammatory chemokines
11 and cytokines in the airway with a subset of these detected in blood, suggesting that systemic
12 cytokines may derive from inflammatory processes originating at the infection site.

13 To define the cellular origin of the chemokines and cytokines detected in each
14 compartment, we analyzed transcript expression for each of the analytes from Figure 5B by
15 scRNA-seq. Overall, transcript expression of prominent cytokines/chemokines largely correlated
16 to the protein data; airway myeloid cells expressed high levels of *CCL2*, *CCL3* and *CCL4*
17 transcripts corresponding to the high levels of the respective proteins in airways, while blood
18 myeloid cells expressed lower or undetectable levels of these transcripts (Figure 5C). Airway and
19 blood myeloid cells also expressed *CXCL8* and *TGFB1*, consistent with the protein data (Figure
20 5C). In the airways, T cells expressed *GZMB*, *CXCL8*, *CCL4*, *PRF*, *IFNG*, and *TGFB1*
21 transcripts, which were expressed by blood T cells at lower or variable levels (Figure 5C).
22 Airway epithelial cells expressed predominantly *CXCL8* transcripts, as well as lower levels of
23 transcripts for IL-7 and several chemokines (Figure 5C). Overall, these results demonstrate

1 compartmentalized secretion of monocyte/macrophage-derived chemokines and inflammatory
2 mediators in the airways with potential roles for recruiting immune cells to the lung that may
3 contribute to lung inflammation and tissue damage.

4

5 **COVID-19-induced features of airway and blood immune cells**

6 To assess COVID-19-related alterations in airway and blood immune cells that could
7 potentially contribute to disease pathogenesis, we obtained baseline controls of blood from
8 uninfected, healthy adults, and airway washes from lungs of SARS-CoV-2-negative organ
9 donors as done previously (Snyder et al., 2019). High-dimensional flow cytometry analysis of
10 control healthy blood (HB) and airway (HA) samples (Table S7), in conjunction with the
11 COVID-19 patient samples from Figure 1 (COVID-19 blood (CB); COVID-19 airway (CA))
12 revealed non-overlapping features of COVID-19 and healthy samples for all lineages and
13 particularly within T cells and monocyte/macrophages (Figure 6A, left). Overall immune cell
14 composition and T:monocyte/macrophage cell ratio were similar in healthy and COVID-19
15 airway samples; however, a dramatic increase in circulating monocyte frequency resulting in a
16 reduced T: monocyte/macrophage ratio was observed in COVID-19 blood relative to healthy
17 controls (Figure 6A, middle and right). By PCA, airway and blood samples were distinct,
18 irrespective of disease; however, healthy and COVID-19 airway samples were intermixed, while
19 healthy blood samples clustered separately from COVID-19 blood samples (Figure 6B). These
20 findings indicate that COVID-19-specific alterations in immune cell composition are manifested
21 more dramatically in blood than in airways.

22 To more closely examine site-specific differences between immune cells in healthy and
23 COVID-19 individuals, we analyzed T cell and monocyte/macrophage populations separately.

1 UMAP embeddings of T cells from blood and airway showed compartmentalized profiles for
2 both healthy and COVID-19 samples (Figure 6C, left). We calculated a Minkowski Distance
3 (MD; see methods) to quantify the similarity in T cell populations across conditions and sites,
4 with higher values denoting greater similarity. T cell populations within each site were similar in
5 healthy and COVID-19 samples (HB v. CB MD = 0.77; HA v. CA MD = 0.74), whereas T cell
6 populations in the two sites were more distinct (HA v. HB MD = 0.39, CA v. CB MD = 0.57)
7 (Figure 6C). Comparing T cells in healthy and COVID-19 samples, there were increased
8 frequencies of CD69⁺CD103⁺ TRM and T cells expressing activation markers HLA-DR and PD-
9 1 in the airways of COVID-19 patients compared to uninfected individuals; these markers were
10 not expressed significantly by blood T cells in COVID-19 nor in healthy controls (Figure 6D).
11 The compartmentalized activation of T cells in airways in COVID-19 provides further evidence
12 for dynamic T cell immunity at the infection site.

13 For monocytes/macrophages, UMAP embeddings revealed compartmentalized profiles
14 between healthy airway and blood, but considerable overlap of monocyte/macrophage profiles
15 between COVID-19 airway and blood (Figure 6E). Accordingly, Minkowski distance
16 calculations confirmed that healthy airway and blood monocyte/macrophage subsets were
17 distinct (MD = 0.47), while in COVID-19 patients airway and blood myeloid cell profiles were
18 more similar (MD = 0.72) (Figure 6E, right). Specifically, CD163, a scavenger receptor typically
19 expressed by tissue macrophages and monocytes in response to inflammation (Buechler et al.,
20 2000), was expressed in control airway macrophages and not by blood monocytes; however, in
21 COVID-19 samples, the proportion of monocytes/macrophages expressing high levels of CD163
22 (CD163^{hi}) was similar in both sites (Figure 6F). Moreover, monocytes in healthy blood samples
23 uniformly expressed HLA-DR and CD86, while monocytes from COVID-19 blood exhibited

1 significantly reduced proportions of HLA-DR^{hi} and CD86^{hi} cells (Figure 6F), consistent with
2 recent findings regarding blood monocyte profiles in severe COVID-19 and suggestive of an
3 immature phenotype (Schulte-Schrepping et al., 2020). Taken together, these results indicate
4 profound alterations in blood monocytes in COVID-19, which also share similar features with
5 airway macrophages, suggesting that airway resident myeloid cells in severe COVID-19 may
6 derive, in part, from these circulating precursors and that interactions between airway and blood
7 myeloid cells may contribute to disease pathology.

8 **Accumulation of CD163⁺ cells in the lungs of severe COVID-19 patients**

9 We hypothesized that the production of monocyte-chemoattractant chemokines by airway
10 monocyte/macrophages along with the elevated levels of CD163⁺ monocytes in COVID-19
11 blood may result in their dysregulated infiltration into the lung. We therefore examined immune
12 cells in lung autopsy samples from COVID-19 patients with diffuse alveolar damage, the main
13 pathological finding associated with COVID-19 ARDS (De Michele et al., 2020), relative to
14 lungs from uninfected, deceased organ donor controls (Carpenter et al., 2018) (Table S7). In the
15 airways of uninfected lungs, T cells were clustered around the airway epithelium, while CD163⁺
16 monocytes/macrophages were dispersed in the parenchyma (Figure 7A, top left). In the lungs of
17 individuals who succumbed to COVID-19 ARDS, there was a marked and dramatic increase in
18 CD163⁺ monocytes/macrophages and damaged airway epithelium that was partially denuded and
19 sloughing off into the lumen (Figure 7A, top right). In particular, CD163⁺
20 monocytes/macrophages aggregated in the alveolar spaces of COVID-19 infected lungs and not
21 in controls, suggesting their participation in lung damage in COVID-19. Quantitative analysis of
22 the lung imaging data showed significant increases in the frequency and density of CD163⁺
23 monocytes/macrophages in COVID-19 versus controls, while lymphocyte content was not

1 similarly increased (Figure 7B). We assessed expression of genes associated with cell cycle or
2 proliferation (*Ki67*, *TOP2A*, *UBE2C*) in monocyte/macrophage populations in the airway or
3 blood by scRNA-seq, revealing no significant expression of these markers (Figure 7C). Together
4 with the high-dimensional analysis of airway immune cells, these findings implicate the
5 recruitment of immature monocytes from the periphery into the lung, where they subsequently
6 become highly pro-inflammatory and drive the pathogenesis of severe COVID-19.

7

1 **DISCUSSION**

2 During the SARS-CoV-2 pandemic, restoration of normal life is impeded first and
3 foremost by the most severe COVID-19 cases, including debilitating ARDS and its high
4 mortality. Numerous studies have now identified characteristic features of innate and adaptive
5 immunity to SARS-CoV-2 infection that are detectable in blood (Kuri-Cervantes et al., 2020;
6 Laing et al., 2020; Lucas et al., 2020; Mathew et al., 2020; Moderbacher et al., 2020; Schulte-
7 Schrepping et al., 2020); however, the initiation, function, and establishment of immune
8 responses for respiratory viruses occur in the lung and respiratory tract. Several studies have
9 separately assessed cellular composition within the respiratory environment in bronchiolar
10 lavage samples and lung autopsies (Damiani et al., 2020; Liao et al., 2020; Veras et al., 2020).
11 Characterizing respiratory immune responses *in situ* in the context of circulating immune cell
12 populations is needed to dissect mechanisms of disease pathogenesis to combat this pandemic.

13 In this study, we obtained paired respiratory and blood samples from patients with severe
14 COVID-19 longitudinally during the course of intensive care hospitalization. We employed high
15 dimensional profiling by spectral flow cytometry and scRNA-seq as well as multiplex cytokine
16 quantification and immunofluorescence imaging to characterize airway and systemic immune
17 responses and their interactions, revealing key insights into disease pathogenesis. Importantly,
18 we found that innate and adaptive immune responses in severe COVID-19 predominate in the
19 respiratory tract and are qualitatively and quantitatively distinct from immune dynamics in the
20 blood. The most striking differences in immune cells between airways and blood were identified
21 within both T cell and monocyte/macrophage populations. Moreover, increased frequencies of T
22 cells and decreased macrophage/monocyte frequencies exclusively in the airways correlate with

1 better outcome and younger age, further indicating key roles for these cells at the infection site in
2 disease pathogenesis.

3 T cells in COVID-19 airways were predominately TRM, most of which exhibited
4 features of activation, including surface phenotypes (HLA-DR^{hi}PD-1^{hi}CD127^{lo}) and upregulated
5 expression of transcripts for effector molecules such as perforin, *GZMB* and *IFNG*. This was not
6 the case in the blood of COVID-19 patients, which lacked TRM and activated T cell profiles.
7 Furthermore, activated TRM were detected specifically in airways of COVID-19 patients and not
8 in airway washes of organ donor controls, indicating a virus-directed response, although
9 insufficient T cell numbers in airways precluded direct measurement of SARS-CoV-2-specific T
10 cells. In mouse influenza infection, the presence of activated lung TRM *in situ* to influenza
11 infection correlates with virus-specific responses (Paik and Farber, 2020; Turner et al., 2014),
12 further supporting that *in situ* activation is a surrogate for anti-viral responses. In human SARS-
13 CoV-2 infection, blood may serve as a consistent and reliable indicator for detection of SARS-
14 CoV-2-specific T cells and the establishment of adaptive immune memory (Grifoni et al., 2020;
15 Moderbacher et al., 2020; Weiskopf et al., 2020). However, our results suggest that measuring
16 global T cell activation markers in the periphery, as done in recent studies (Mathew et al., 2020;
17 Takahashi et al., 2020), may not provide an accurate assessment of the virus-targeted immune
18 response *in situ* during active disease.

19 Airway monocytes/macrophages in COVID-19 patients differed significantly from their
20 blood cell counterparts, with increased frequencies of activated subsets, increased expression of
21 transcripts associated with tissue macrophages (e.g. *MARCO*, *MRC1*, *ITGAV*), and high-level
22 expression of genes encoding pro-inflammatory mediators such as *CCL2*, *CCL3*, *CCL4*,
23 *CXCL8*, matrix metalloproteases, and complement components. Consistent with this

1 inflammatory profile, excessive levels of MCP-1/CCL2, MIP-1 α /CCL3, and MIP-1 β /CCL4
2 protein were detected in the airways, but not in blood, further supporting a role of airway
3 macrophages in initiating and perpetuating the inflammatory responses in severe COVID-19.
4 This phenotypic and functional profile of COVID-19 airway monocytes/macrophages shares
5 features with human macrophages in ARDS due to non-infectious causes, including the
6 production of CCL2 and CXCL8, as well as induction of MMPs and complement (Aggarwal et
7 al., 2014; Morrell et al., 2019). In ARDS, CCL2-expressing airway macrophages recruit
8 inflammatory monocytes expressing the CCL2 binding receptor CCR2, which contribute to lung
9 damage; airway macrophages can subsequently facilitate repair through TGF- β production
10 (Aggarwal et al., 2014). Our results indicate that COVID-ARDS shares some key features with
11 ARDS resulting from other infectious or non-infectious causes.

12 Our coordinate analysis of airway and blood myeloid cells and soluble mediators suggest
13 an analogous role for airway macrophages driving lung damage in COVID-19 ARDS through
14 recruitment of circulating monocytes. We show that blood monocytes in severe COVID-19
15 express increased levels of CCR2 transcripts and aberrant CD163⁺HLA-DR^{lo}/CD86^{lo} phenotypes
16 compared to healthy blood monocytes. Reduced HLA-DR expression indicative of immature
17 monocytes has been identified in blood myeloid cells in severe COVID-19 (Schulte-Schrepping
18 et al., 2020; Silvin et al., 2020) and may derive from inflammation-induced mobilization of
19 immature monocytes from the bone marrow, termed emergency myelopoiesis (Schultze et al.,
20 2019; Shi et al., 2011; Venet et al., 2020). While a cytokine storm marked by elevated levels of
21 serum cytokines is implicated in pathogenesis of severe COVID-19 and emergency myelopoiesis
22 (Chau et al., 2020; Copaescu et al., 2020; Lucas et al., 2020; Schulte-Schrepping et al., 2020),
23 our results show that inflammatory cytokines detected in the blood lacked CCL2 and other

1 chemokines, which direct recruitment of multiple immune cell types. Our findings rather suggest
2 that pro-inflammatory cytokines emanating from the respiratory tract recruit circulating
3 inflammatory monocytes to the lungs and perpetuate lung damage. Immunofluorescence imaging
4 of lungs from severe COVID-19 patients shows a striking increase in CD163-expressing
5 monocytes/macrophages within the damaged lung tissue that lack proliferative signatures and
6 therefore likely derive from recruitment. These cells specifically accumulate in the alveolar
7 spaces of the lungs, a key site for blood gas exchange, suggesting their involvement in diffuse
8 alveolar damage commonly seen in COVID-19 pathology (De Michele et al., 2020).

9 Our results defining airway immune responses in COVID-19 and their relation to the
10 corresponding immune reactants in blood have profound implications for treating and preventing
11 disease. Treatments targeting systemic inflammation, either globally with steroids or specifically
12 with cytokine blockade, have shown variable efficacy in severe COVID-19 (Della-Torre et al.,
13 2020; Furlow, 2020). Our results suggest that targeting airway-derived cytokines such as CCL2
14 through CCR2 antagonists or other airway-specific mediators may be more effective in reducing
15 lung damage or even promoting recovery from ARDS in severe COVID-19. A similar role for
16 CCL2-mediated monocyte recruitment in lung pathology was demonstrated in mouse models of
17 influenza infection (Lin et al., 2008; Lin et al., 2011), suggesting a generalized mechanism for
18 respiratory virus-induced lung injury. Because our scRNA-seq analysis showed that the elevated
19 airway mediators derive chiefly from the lung macrophages, treatments which regulate these
20 cells may also mitigate the clinical course of disease.

21 Our finding that increased proportions of airway T cells are associated with better
22 outcome and younger age suggests that promoting lung-localized immune responses is an
23 important consideration for vaccine design. In mouse models, intranasal administration of the

1 live-attenuated influenza vaccine or bacterial-based vaccines can promote establishment of lung
2 TRM that mediate protective immunity to pathogen challenge (Allen et al., 2018; Zens et al.,
3 2016). Intravenous administration of the BCG vaccine to non-human primates was recently
4 shown to generate substantial populations of lung TRM, which correlated strongly with
5 protection from tuberculosis (Darrah et al., 2020). The current SARS-CoV-2 vaccines in phase
6 III trials target generation of neutralizing antibodies and are robust strategies for establishing
7 sterilizing immunity (Jeyanathan et al., 2020); however, respiratory targeting could be
8 considered for individuals who are unable to develop effective antibody responses. These cohorts
9 may include the immunocompromised or the elderly, or this strategy could be used as a booster
10 for those at risk for infection due to frequent interactions with others through their living or work
11 situations. Indeed, a recent pre-clinical study demonstrated that intranasal administration of a
12 recombinant SARS-CoV-2 vaccine promoted lung TRM generation and protection from viral
13 challenge in a mouse model (Hassan et al., 2020).

14 In summary, our study provides a dynamic view of ongoing respiratory immunity in
15 severe COVID-19, revealing compartmentalization of protective and pathogenic immune
16 responses in the lung. These findings have important implications for how we monitor, treat and
17 protect from this pandemic and future infectious challenges to the respiratory tract.

1 **Acknowledgements**

2 We wish to express our gratitude to the Medical ICU nurse champions, Cora Garcellano, Tenzin
3 Drukduk, Harriet Avila Raymundo, Lori Wagner, and Ricky Lee, who led the efforts to obtain
4 patient samples for the adult ARDS patients, to Evelyn Hernandez and Lorena Gomez for their
5 roles as clinical coordinators, and to the nurses and clinical staff in the Pediatric Intensive Care
6 Unit of MSCHONY. We acknowledge the dedication, commitment, and sacrifice of the other
7 nurses, providers, and personnel who helped care for these patients during the COVID-19 crisis.
8 We acknowledge the suffering and loss of our COVID-19 patients and of their families and our
9 community. We also gratefully acknowledge the generosity of the donor families and the
10 exceptional efforts of LiveOnNY transplant coordinators and staff for the donor lungs.

11 This work was supported by NIH grants AI128949 and AI06697 awarded to D.L.F., a Chan
12 Zuckerberg Initiative COVID-19 grant to D.L.F. and P.A.Sims, and an R01AI093870 awarded to
13 A.J.Y. P.D. was supported by a CRI-Irvington Postdoctoral Fellowship and P.A.S. by a Canadian
14 Institutes of Health Research Fellowship. T.J.C. is supported by NIH K23 A1141686 and S.P.W.
15 is supported by NIH K08 DK122130. Research reported in this publication was performed in the
16 Human Immune Monitoring Core, the Columbia Single Cell Analysis Core, and the Sulzberger
17 Columbia Genome Center, which are supported by an NCI cancer center support grant
18 P30CA013696. The content is solely the responsibility of the authors and does not necessarily
19 represent the official views of the National Institutes of Health. We thank Eldad Hod for use of
20 his laboratory for sample processing, and Carly Ziegler and Dr. Alex Shalek of MIT for sharing
21 their merged human / SARS-CoV-2 genome and transcriptome annotation.

22 **Author Contributions**

1 P.A.Sz., S.W., J.G., P.D. processed samples, designed and optimized high-dimensional flow
2 cytometry panels, analyzed data, made figures, and wrote the manuscript. P.A.Sz. and S.W.
3 processed samples for scRNAseq profiling and encapsulation using 10X Chromium; I.K.
4 prepared and sequenced the 10X libraries. P.D. designed the Python pipeline for flow cytometry
5 data. M.B. monitored and consented ICU patients, oversaw clinical data analysis ,and collected
6 samples. T.C. obtained and maintained IRB protocols, consented patients, and processed
7 samples. M.M.L.P., R.M., E.I., M.C. obtained and processed patient samples. S.E.M., C.P., and
8 A.JY. statistically analyzed longitudinal data; J.D.-P. captured and analyzed patient data; J.Z.,
9 M.S. S.M. performed cytokine analysis of airway supernatants and blood plasma; S.P.W.
10 planned, designed, and analyzed lung autopsy imaging experiments; A.S. provided lung autopsy
11 samples and associated data; A.K. performed immunohistochemistry of lung autopsies. P.A.Sims
12 planned scNAseq experiments, analyzed data, and, wrote and edited manuscript. D.L.F. oversaw
13 compliance, planned experiments, coordinated sample acquisition and data acquisition/analysis,
14 analyzed data, and wrote and edited the paper.

15 **Declaration of Interests**

16 J.Z., M.S. and S.M. have competing interests with IsoPlexis. The remaining authors declare no
17 competing interests.

1 **FIGURE LEGENDS**

2 **Figure 1. Distinct immune cell composition in airways compared to blood is associated with**
3 **outcome and age** (A) Schematic diagram showing assays performed on COVID-19 patient
4 airway and blood samples for this study. (B) Principal component analysis (PCA) of all COVID-
5 19 samples based on mean marker expression colored by site (left), outcome (middle) and by
6 donor (right). (C) UMAP embedding of flow cytometry results from all airway and blood
7 samples combined colored by major cell lineage (top panel), and separated by tissue site (bottom
8 two panels). (D) Immune cell composition over time in airways and blood. Box plots show the
9 frequency of each major cell lineage of CD45⁺CD66B⁻ cells in airway (left) and blood (right)
10 samples collected longitudinally for each sample day. Color of boxes corresponds to lineage and
11 each dot is an individual patient sample. (E) Hierarchical clustering of airway (left) and blood
12 (right) samples based on average lineage frequency across all time points for each donor-site
13 group. Heatmaps are colored by row normalized value for each sample. (F) Line plots showing
14 frequency of major lineages of total CD45⁺CD66B⁻ cells in airway (top row) and blood (bottom
15 row) samples collected longitudinally for representative donors. (G) Association of
16 monocyte/macrophage and T cell frequencies in airway (left) and blood (right) with outcome
17 (deceased or survived) and correlation with age. Statistical significance was calculated using
18 Mann-Whitney U-tests (box-plots) or Pearson correlations (scatter plots) and indicated by ***, p
19 ≤ 0.001 ; **, $p \leq 0.01$; *, $p \leq 0.05$.

20 **Figure 2. Airway T cells in COVID-19 are dominated by TRM and activated phenotypes.**

21 (A) Heatmap displaying expression of markers within phenograph-generated, hierarchical T cell
22 clusters. The 27 phenograph clusters were collapsed into 15 definable cell subsets indicated at
23 bottom. Heatmap data are colored by row normalized value for each sample. (B) UMAP

1 embedding of 15 T cell subsets in the airway (upper) and blood (lower) with labels denoting the
2 specific subset as defined in A. (C) T cell subset frequencies in airway compared to blood
3 samples. Boxplots showing frequency of the indicated T cell subset for each patient (average of
4 all time points collected) in the airway (blue) and blood (red). Statistical significance was
5 calculated using a paired T-tests and indicated by ***, $p \leq 0.001$; **, $p \leq 0.01$; *, $p \leq 0.05$. (D)
6 Frequencies of the major T cell subsets in airway and blood shown for each individual patient
7 and their outcome in airway (left) and blood (right) shown in a heat map. (only select subsets
8 shown) (E) Heatmap showing major differentially expressed genes in airway compared to blood
9 T cells by scRNA-seq from each individual patient and timepoint. Data are colored by row z-
10 score for each sample. (F) Separate UMAP embeddings of gene expression by scRNA-seq from
11 total T cells obtained from airway and blood of paired samples from four patients. UMAP shows
12 airway (blue) and blood (red) origin of samples, patient, and indicated gene expression (based on
13 $\text{Log}_2(\text{CPM}+1)$).

14 **Figure 3. Monocyte/macrophage lineage cells are activated in airway of COVID-19 patients**

15 (A) UMAP embedding of aggregated flow cytometry data obtain in Figure 1 showing expression
16 of major myeloid markers in airway and blood. (B) Mean expression of each myeloid-associated
17 marker within the airway (blue) or the blood (red) samples shown as boxplots with each dot
18 representing individual patient data averaged for all timepoints (C) Heatmap displaying
19 expression of markers within phenograph-generated, hierarchical monocyte/macrophage clusters.
20 The 20 phenograph clusters were collapsed into 6 cellular subsets based on common myeloid
21 nomenclature – classical, intermediate and non-classical, and whether they were activated
22 (“Act.”). Heatmap data are colored by row normalized value for each sample. (D) UMAP
23 embedding of the different subsets colored as in C from airway and blood samples. (E) Boxplots

1 showing compiled frequency of each monocyte/macrophage subset displayed as an average of all
2 time points collected on a per donor basis. Statistical significance was calculated using a paired
3 T-test and indicated by ***, $p \leq 0.001$; **, $p \leq 0.01$; *, $p \leq 0.05$.

4 **Figure 4. Airway contains tissue macrophages and monocytes with highly inflammatory**
5 **profiles compared to blood** (A) Monocyte/macrophage profiles in airway and blood were
6 analyzed by scRNAseq. Gene expression analysis of scRNAseq of subset-defining genes,
7 homing receptors and key inflammatory molecules for monocyte/macrophages in airway and
8 blood from each patient sample (left). The heatmap shows genes that are not differentially
9 expressed between airway and blood (*CD14-FCGR3A*) and genes are consistently differentially
10 expressed (*ITGAV-TREM2*). UMAP embedding of total monocyte/macrophage cells obtained
11 from airway (blue dots) and blood (red dots) compiled from four patient samples (right). (B)
12 Expression levels of the IFN response genes between airway and blood (left). UMAP embedding
13 displaying the expression levels of the IFN response genes in individual cells (right) displayed as
14 $\log_2(\text{CPM}+1)$.

15 **Figure 5. COVID-19 airways contained highly elevated levels of myeloid and T cell-derived**
16 **cytokines compared to blood** (A) Levels of indicated cytokines and chemokines in the airway
17 (top) and plasma (bottom) compiled from 15 patients depicted in box plots showing \log_{10}
18 normalized cytokine expression profiles for an early and late time point (see methods). Each dot
19 represents an individual data point. (B) Heatmap showing $\log_{10}(X+1)$ pg/mL cytokine levels
20 averaged across both time points in airway (left) and blood plasma (right) samples for each
21 donor. (C) Transcript levels for cytokine expression by major cell lineages identified in by
22 scRNA-seq for each patient samples indicated by color. Heatmap shows $\log_2(\text{mean CPM}+1)$
23 gene expression.

1 **Figure 6. Defining COVID-19-associated immune responses relative to healthy blood and**
2 **airway samples.** Blood was obtained from healthy adults and airway samples from lungs of
3 SARS-CoV-2-negative organ donors; immune cells were stained with the flow cytometry panel
4 in Figure 1 and analyzed in conjunction with COVID-19 patient samples. (A) Comparison of
5 major immune cell lineages in healthy (n=6 airway and 5 blood) and COVID-19 airway (n=54)
6 and blood (n=54) samples. *Left:* UMAP embedding of samples colored by condition (healthy –
7 purple; COVID-19 – orange). *Middle:* Box plots showing the frequency of indicated immune
8 cells from total CD45⁺CD66B⁻ cells for each site. Each dot is the average of all time points per
9 patient/donor. *Right:* Ratio of T: monocyte/macrophage for each site and condition. (B) PCA of
10 mean marker expression (average of each time point for COVID-19 samples) for COVID-19
11 airway (blue), healthy airway (yellow), COVID-19 blood (black) and healthy blood (red). (C) T
12 cell compartmentalization in airways and blood in health and COVID-19. *Left:* UMAP
13 embedding of the T cell expression data for COVID-19 and healthy controls across airway and
14 blood (upper two panels). *Right:* Correlation heatmaps calculated using Minkowski distance
15 (MD) measures (shown in heat maps as 1-MD) with higher values indicating greater similarity
16 between two samples. HA – healthy airway, HB – healthy blood, CA – COVID-19 airway, CB –
17 COVID-19 blood. (D) Expression of T cell residency and activation markers in airway and blood
18 of healthy and COVID-19 samples. *Left:* Contour plots showing mean expression of indicated
19 markers within the airway (blue contours) and blood (red contours) by condition (healthy or
20 COVID-19). *Right:* Boxplots show frequency of cells expressing indicated markers, for each
21 sample. (E) Monocyte/macrophage compartmentalization in airways and blood in health and
22 COVID-19. *Left:* UMAP embedding of the monocyte/macrophage compartment of COVID-19
23 and healthy controls across airway and blood (upper two panels). Lower panels indicate

1 correlation heatmap as an average by condition and site (lower right panel). Minkowski distance
2 metric calculated as in D but for myeloid cells. HA – healthy airway, HB – healthy blood, CA –
3 COVID-19 airway, CB – COVID-19 blood. (F) Expression of monocyte/macrophage markers in
4 airway and blood. *Left*: Contour plots showing indicate mean expression of indicated markers by
5 monocyte/macrophages in airway (blue contours) and blood (red contours) samples by condition
6 (healthy or COVID). *Right*: Boxplots indicate percentage of cells within each condition and site
7 that were positive for specific markers, given as an average over all time points for COVID-19
8 samples. Statistical significance was calculated using a one-way ANOVA followed by a Tukey
9 HSD and indicated by ***, $p \leq 0.001$; **, $p \leq 0.01$; *, $p \leq 0.05$.

10 **Figure 7. Lung pathology in COVID-19 shows extensive accumulation of CD163⁺ cells**
11 **associated with cellular recruitment.** (A) Lung sections obtained from non-diseased organ
12 donors and autopsy specimens from COVID-19 patients with diffuse alveolar damage were
13 stained with indicated antibodies and analyzed using Vectra. Representative images show T cell
14 (CD4, CD8), and monocyte/macrophages (CD163) staining in the lungs of uninfected controls
15 (left) and COVID-19 patients (right). (B) Quantitation of T cell and monocyte/macrophage
16 content in control (n=2) and COVID-19 (n=5) lungs as a frequency of total lung cells or density
17 (cells per mm² cellular area) using InForm software. Statistical significance indicated by ***, $p \leq$
18 0.001; **, $p \leq 0.01$; *, $p \leq 0.05$. (C) Expression of genes associated with proliferation by scRNA-
19 seq in monocyte/macrophages derived from airway and blood as in Figure 4.

20

1 Supplemental Figure Titles and Legends

2 **Figure S1. Gating strategy for flow cytometry analysis** (A) FACS plots denoting the gating
3 strategy used for analysis of myeloid and lymphocyte populations using the Aurora flow
4 cytometry from complex populations in airway samples, with complementary gating for blood
5 cells. Total cells were initially gated on CD45⁺ cells versus time to eliminate non-hematopoietic
6 cells and debris; doublets were excluded followed by exclusion of neutrophils (FSC-A^{hi}
7 CD66b⁺). Finally, dead cells were excluded by gating on CD45 and LIVE/DEAD blue. The
8 resulting populations contained the full complement of mononuclear immune cells used for
9 downstream analysis.

10 **Figure S2. Expression of lineage defining markers determined by flow cytometry and**
11 **scRNA-seq** (A) UMAP embedding displaying expression of lineage-defining markers for the
12 major immune cell subsets in combined airway and blood samples from 13 COVID-19 patients.
13 (B) Heatmap of scRNA-seq data displaying gene expression of lineage defining markers for both
14 the airway and blood across the four donors. Heatmap data are colored by $\log_2(\text{CPM}+1)/\max$
15 values for each sample.

16 **Figure S3. Major immune cell lineages over time in COVID-19 patients.** (A) Individual
17 patient data displaying the proportion of each major immune cell lineage over the time course of
18 sample collection. D – deceased, S – survived. (B) Classification performance of longitudinal K-
19 means clustering for different combinations of immune cell trajectories. The percentage of donor
20 outcomes that were successfully classified as deceased or survived is shown when all subsets,
21 only myeloid and T cells, only myeloid, or only T cells were used for clustering. Colors denote
22 whether airway, blood, or both airway and blood trajectories were included. (C) Association of

1 ILC, B cells, T:myeloid and CD4:CD8 content in airway (left) and blood (right) with outcome
2 (deceased or survived) and correlation with age. Statistical significance was calculated using
3 Mann-Whitney U-tests (box-plots) or Pearson correlations (scatter plots) and indicated by ***, p
4 ≤ 0.001 ; **, $p \leq 0.01$; *, $p \leq 0.05$.

5 **Figure S4. T cell marker expression in the airways and blood of COVID-19 patients.** (A)
6 UMAP embeddings indicate site of origin for total T cells in the airway and blood of COVID-19
7 patients (top left) and expression of indicated T cell markers. (B) Boxplots showing mean of
8 scaled expression of T cell markers on total T cells for each patient averaged across all
9 timepoints, Statistical significance was calculated using a paired T-test and indicated by ***, $p \leq$
10 0.001 ; **, $p \leq 0.01$; *, $p \leq 0.05$.

11 **Figure S5. B cell subsets in airway and blood** (A) UMAP embedding of the expression of key
12 B cell markers in airway and blood samples. (B) Boxplots showing mean of scaled expression of
13 B cell markers on total B cells for each patient averaged across all timepoints, (C) Heatmap
14 displaying expression of markers within phenograph-generated clusters for B cell subsets. The
15 12 phenograph clusters were collapsed into 9 subsets designated on the bottom row. Heatmaps
16 are colored by row normalized expression values. (D) UMAP embedding of 9 B cell subsets in
17 the airway and blood. (E) Boxplots showing frequency of each B cell subset among total B cells
18 for each patient averaged across all timepoints, Statistical significance was calculated using a
19 paired T-test and indicated by ***, $p \leq 0.001$; **, $p \leq 0.01$; *, $p \leq 0.05$.

20 **Figure S6 related to Figure 4. IFN and IFN-related gene signature in COVID-19 airways.**
21 Heatmap showing $\log_2(\text{CPM}+1)$ expression of *IFN* and *IFN*-related genes by the indicated
22 airway cell types as determined by scRNA-seq for each patient sample, indicated by color.

1

2 **Figure S7. Airway is the major site for production of inflammatory cytokines and**
3 **chemokines in COVID-19 patients.** (A) Box plots showing $\log_{10}(X+1)$ normalized cytokine
4 expression profiles in the airway wash (left) and blood plasma (right) samples for an early and
5 late time point collected from 15 donors. Each dot represents an individual data point. (B)
6 Pairwise comparison of cytokine levels averaged across both timepoints in airway wash and
7 blood plasma samples collected from 15 donors. A p-value of < 0.05 was considered significant.
8 For figures, p-value $< 0.05 = *$, p-value $< 0.01 = **$ and p-value $< 0.001 = ***$.

9

10

11

1 **Methods**

2 **LEAD CONTACT AND MATERIALS AVAILABILITY**

3 Further information and requests for reagents should be directed to and will be fulfilled by lead
4 author Donna L. Farber (df2396@cumc.columbia.edu)

5
6 **Materials Availability Statement**

7 This study did not generate new unique reagents.

8
9 **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

10
11 **Human samples**

12 We recruited patients from and CUIMC/NYP and Morgan Stanley Children's Hospital of NY
13 with severe COVID-19 and ARDS (n=15) who tested positive for SARS-CoV-2 by polymerase
14 chain reaction (PCR) from nasopharyngeal swabs (Table S1, S2). Blood and airway sampling
15 began within 24-36 hours for all patients. ARDS was defined by clinical consensus criteria;
16 including infiltrates on chest radiograph and a PaO₂/FiO₂ ratio of less than 300, or pediatric
17 criteria equivalent (Khemani et al., 2015; Ranieri et al., 2012). Sequential Organ Failure
18 Assessment (SOFA) scores were calculated on all hospitalized patients using previously
19 validated adult and pediatric score tools to provide additional clinical insight into patient disease
20 severity (Matics and Sanchez-Pinto, 2017; Singer et al., 2016; Vasilevskis et al., 2016). All
21 patients and samples in this study were enrolled on protocols approved by the Institutional
22 Review Board at CUIMC. Due to the limitations placed on direct contact with infected patients
23 and a need to conserve personal protective equipment, verbal informed consent was obtained

1 from surrogates of critically ill COVID-19-ARDS patients. Healthy blood was obtained from 5
2 adult volunteers 31-57 years.

3 Control, non-diseased lung tissues were obtained from deceased organ donors as part of
4 organ acquisition for clinical transplantation through an approved protocol and material transfer
5 agreement with LiveOnNY as described previously (Carpenter et al., 2018; Dogra et al., 2020).
6 Donors were free of cancer, chronic diseases, seronegative for hepatitis B, C, and HIV, and
7 negative for SARS-CoV-2 by PCR (Table S7). Use of organ donor tissues does not qualify as
8 “human subjects” research, as confirmed by the Columbia University IRB as tissue samples were
9 obtained from brain-dead (deceased) individuals.

10

11 **Processing of blood samples and isolation of PBMCs from COVID-19 patients**

12 Whole blood collected in heparinized vacutainers was centrifuged at 400 x g for 10 min at room
13 temperature (RT) to isolate plasma, which was then stored at -80°C for subsequent analysis.
14 PBMCs were isolated using Ficoll-Paque PLUS (GE) density gradient centrifugation in a
15 Biosafety Level 2+ facility. To remove neutrophils, blood was incubated with RosetteSep
16 Granulocyte Depletion Cocktail (Stemcell Technologies), diluted 1:3 in room temperature
17 DPBS, layered over Ficoll-Paque PLUS in 50mL conical tubes, and centrifuged for 20 min at
18 1,200 x g. The PBMC layer was isolated according to the manufacturer’s instructions. Cells were
19 washed twice with DPBS before counting with the automated NucleoCounter NC-3000 cell
20 counter (ChemoMetec).

21

22 **Processing of airway samples and isolation of airway MNCs from COVID-19 patients**

1 To collect airway supernatants, DPBS was added 1:1 directly to airway samples and centrifuged
2 at 400 x g for 10 min at RT. The resulting supernatants were stored at -80°C for subsequent
3 analysis. To isolate airway MNCs, samples were treated with Benzonase (Millipore Sigma),
4 purified through 100 μm filters, and centrifuged on a density gradient using Ficoll-Paque PLUS.
5 The MNC layer was isolated according to the manufacturer's instructions. Cells were washed
6 twice with DPBS before counting with the automated NucleoCounter NC-3000 cell counter
7 (ChemoMetec).

8

9 **Cell preparation for scRNA-seq, library generation and sequencing**

10 Airway and blood MNC populations were isolated as above, and the remaining neutrophils and
11 red blood cells were removed by incubating samples with biotinylated anti-CD66b and anti-
12 CD235ab antibodies, and depleting antibody-bound cells with streptavidin-coated magnetic
13 beads (Bangs Labs). Dead cells were subsequently removed using the Dead Cell Removal kit
14 (Miltenyi Biotec). The Next GEM Chromium Controller (10x Genomics) and Chromium Next
15 GEM Single Cell 3' Reagent kit v3.1 (10x Genomics) was used for co-encapsulation and
16 scRNA-seq library construction as per manufacturer's suggested protocols. Libraries were
17 sequenced on an Illumina NovaSeq 6000, targeting $\sim 300\text{M}$ raw reads per sample ($\sim 60,000$ raw
18 reads per cell). Sample details and number of cells sequenced in each are shown in Table S3.

19

20 **Isolation of airway washes from non-diseased lungs**

21 Non-diseased lungs were obtained from deceased organ donors as described above. Airway
22 washes were obtained by flushing out the major airway with 60 mL saline as described (Snyder

1 et al., 2019). Cells were pelleted by centrifugation, resuspended in D-PBS and stained with
2 antibodies for flow cytometry.

3

4 **High Dimensional Flow cytometry**

5 For high parameter analysis using the Cytex Aurora panel, 5×10^6 cells from each site were
6 stained in 5 mL U-bottom tubes in the dark using the following antibody panel; Anti-Human
7 HLA-DR-BUV395, Anti-Human CD16-BUV496, Anti-Human CD163-BUV563, Anti-Human
8 CD33-BUV615, Anti-Human PD-1-BUV661, Anti-Human CD56-BUV737, Anti-Human CD64-
9 BUV805, Anti-Human CCR7-BV421, Anti-Human CD86-SB436, Anti-Human CD28-eFluor
10 450, Anti-Human CD8-BV480, Anti-Human CD20-Pacific Orange, Anti-Human CD3-BV510,
11 Anti-Human CD45RA-BV570, Anti-Human CD25-BV605, Anti-Human CD27-BV650, Anti-
12 Human CD69-BV711, Anti-Human CXCR5-BV750, Anti-Human CD335-BV785, Anti-Human
13 CD103-BB515, Anti-Human CD66b-FITC, Anti-Human CD14-Spark Blue 550, Anti-Human
14 CD45-PerCP, Anti-Human CD57-PerCP-Cy5.5, Anti-Human TCR gamma/delta-PerCP-eFluor
15 710, Anti-Human CD1338-PE, Anti-Human CD4-eFlour 568, Anti-Human CD123-PE-CF594,
16 Anti-Human CD95-PE-Cy5, Anti-Human CD11c-PE-Cy7, Anti-Human CD19-Spark NIR, Anti-
17 Human CD127-APC-R700, Anti-Human KLRG1-APC/Fire 750, Anti-Human FoxP3-Alexa
18 Fluor 647. Briefly, cells were washed with DPBS, re-suspended in 1 mL of viability dye and
19 incubated at RT in the dark for 10 min. Following incubation, cells were washed once with cold
20 FACS-buffer (DPBS + 2% FBS + 0.1 mM EDTA) and re-suspended in 200 μ l FASC-buffer + 10
21 μ l human TrueStain FcX + 10 μ l of True-Stain Monocyte Blocker and incubated in dark for 15
22 minutes. Following incubation, cells were washed once with cold FACS-buffer and stained in a
23 two-step process. First, the cells were resuspended in a cell-surface marker staining cocktail and

1 incubated on ice for 20 min. For intracellular staining, surface stained cells were fixed for 25min
2 at RT in fixing buffer (Invitrogen cat# 00-5123-43), followed by staining in permeabilization
3 buffer (Invitrogen cat# 00-8333-56) at RT for 30 min. Cells were washed and data was collected
4 on 5-laser Cytex[®] Aurora machine (Cytex Bio).

5

6 **Highly-multiplexed CodePlex chip secretome proteomics**

7 Cryopreserved tracheal washes and plasma were thawed at room temperature for 30-60 minutes
8 and mixed well by pipetting up and down prior to loading. An aliquot of 5.5 μ L of each sample
9 was pipetted into each macrochambers of a CodePlex chip pre-patterned with a complete copy of
10 a 23-plex antibody array. 2% BSA/PBS was used as background control. The chip was then
11 loaded into an IsoLight automation system and various proteins were measured by fluorescence
12 ELISA and analyzed by the IsoSpeak software using the IsoPlexis Human Adaptive Immune
13 Panel: GM-CSF, Granzyme B, IFN- γ , IL-10, IL-13, IL-15, IL-17A, IL-2, IL-4, IL-5, IL-6, IL-7,
14 IL-8, IL-9, IP-10, MCP-1, MIP-1 α , MIP-1 β , Perforin, sCD137, TGF- β 1, TNF- α , TNF- β .

15

16 **Multispectral staining and imaging of lung tissue**

17 Representative samples of lung tissue 0.5–1.0 cm in thickness were recovered from organ donors
18 and autopsy cases of individuals diagnosed with COVID-19 and found on post-mortem exam to
19 have pathological findings consistent with diffuse alveolar damage (Table S7). Samples were
20 fixed in 10% formalin (Anatech Ltd.) for 48 hours prior to dehydration and embedding in
21 paraffin. These Lung samples were sectioned at 5-mm thickness and stained using 7-color
22 multispectral Opal reagents (Anti-human CD19-Opal 540, Anti-human CD8-Opal 690, Anti-
23 human CD163-Opal 650, Anti-human CD4-Opal 520, Anti-human GzmB-Opal 570, Anti-human

1 CD3-Opal 620) (Akoya Biosciences, Cat# NEL811001KT) as previously described (Gartrell et
2 al., 2018; Weisberg et al., 2019). The multiplex panel included DAPI (BioLegend cat# 422801)
3 for nuclear counterstaining, CD4 (1:150 dilution), CD8 (1:600 dilution), CD163 (1:200 dilution),
4 granzyme B (GzmB) (1:200 dilution), CD19 (1:50 dilution), CD3 (1:500 dilution). Single
5 controls and an unstained slide were stained with each group of slides. After staining, the
6 sections were mounted in Vectashield Hard Set mounting media (Vector Labs, Cat#H1600) and
7 stored at 4⁰C for up to 48 hours prior to image acquisition. Multispectral imaging and acquisition
8 at 20x magnification (numerical aperture 0.75) was performed using the integrated Vectra
9 3automated quantitative pathology imaging system (PerkinElmer) as previously
10 described(Weisberg et al., 2019). Images were analyzed using inForm software (PerkinElmer).
11 Representative areas (10-30) from each donor were chosen for quantitative analysis.

12

13 **Data Analysis**

14 *Flow cytometry analysis*

15 Flow cytometry data was pre-gated to exclude any doublets, dead cells and CD66b⁺ granulocytes
16 using FlowJo v 10.7 (Tree Star) (Figure S1). Cleaned data was exported as .fcs files with
17 compensated parameters and analyzed further and visualized using a Python (v3.7) (Python
18 Software Foundation. Python Language Reference, version 2.7.) computational pipeline. In brief,
19 first the data was filtered to remove any noise using quantile gates; events that fell below 0.01%
20 of marker expression intensity were removed from the sample. Following initial filtering, data
21 from COVID-19 and healthy samples was merged after subsetting 70,000 events from each
22 sample. Any sample with fewer than 1000 events was removed from further analysis. The
23 merged dataset as was transformed using arcsinh function from Python *numpy* library(van der

1 Walt et al., 2011) after manually adjusting the cofactor for each marker. Following
2 normalization, the dataset was normalized on a 0-1 feature scale for each marker using
3 MinMaxScaler function from Python *scikit-learn* library (Pedregosa et al., 2011). The cleaned,
4 transformed and scaled dataset was used to run the first round of *Uniform Manifold*
5 *Approximation and Projection* (UMAP) (McInnes et al., 2018) dimensionality reduction to
6 remove any residual granulocyte contamination identified as clusters of CD45^{lo}CD66b⁺ cells.
7 The resulting “no neutrophil dataset” dataset was split into COVID-19 and healthy samples and
8 used for downstream analysis.

9 For further analysis we downsampled the “no neutrophil COVID-19 dataset” to include
10 20,000 events from each of 141 longitudinal samples and was used to run PCA analysis at
11 sample level using mean expression of markers in each sample, PCA loadings provided in Table
12 S3. We ran UMAP dimensionality reduction (k = 60) on this dataset using 14 lineage-defining
13 markers (CD11c, CD14, CD16, CD19, CD27, CD3, CD4, CD8, CD64, CD56, CD33, CD335,
14 CXCR5, HLA-DR). The data were projected in 2-dimensions using UMAP embeddings and
15 clusters of major immune cell types (CD4 and CD8 T cells, B cells, NK/ILC and
16 Monocytes/Macrophages) were identified based on expression of lineage defining markers
17 (Figure S2B). The frequency of each lineage was averaged for individual donor-site group across
18 all time points and used for hierarchical clustering of samples using “ward” method and
19 “jensenshannon” metric.

20 For lineage specific analysis, we ran UMAP dimensionality reduction and subsequent
21 *Phenograph* clustering (Levine et al., 2015) on each lineage specific dataset using cell subset
22 defining markers selected based on literature review. Markers used for T cell UMAP are shown
23 in Figure S4A. B cell markers used are shown in Figure S5A and monocyte/macrophages shown

1 in Figure 3A. Major cell subset clusters were identified and functionally similar subsets were
2 coalesced and manually annotated. Heatmaps were generated for average marker expression in
3 each cluster. Data are presented as row normalized expression of marker across all clusters.

4 For analysis of COVID-19 and healthy samples, paired blood and airway samples across
5 all timepoints from COVID-19 donors were downsampled to 5,000 events, and each healthy
6 airway and blood sample was downsampled to 30,000 events and merged to create a reduced “no
7 neutrophil Healthy + COVID-19 dataset”. UMAP dimensionality reduction and identification of
8 major cell lineages was done as described above for the COVID-19 dataset. To evaluate
9 similarity of samples by condition-site i.e. healthy-blood, healthy-airway, COVID-19-blood and
10 COVID-19-airway we calculated Minkowski distance metric (MD) (Li et al., 2011) for the
11 samples on scaled marker expression values for individual lineages using Python scipy library
12 (Jones et al., 2001). Data are presented as 1-MD (Minkowski similarity) on the heatmap; higher
13 numbers indicate increased similarity and lower numbers indicate reduced similarity between
14 samples. All graphs were generated using the Python *matplotlib* and *seaborn* libraries (Hunter,
15 2007).

16

17 ***Classifying donor outcomes using longitudinal K-means clustering***

18 Donors were partitioned into two groups using a longitudinal K-means algorithm applied to the
19 trajectories of the frequencies of myeloid, B cell, CD4 and CD8 T cell and ILC frequencies in
20 blood and/or airways. The proximity of two donors’ trajectories was defined using the sum of the
21 squared Euclidean distances between their subset frequencies at each location at each timepoint,
22 after normalizing each subset frequency across all donors and timepoints. The clustering
23 outcome was robust to this definition of distance, giving identical results when performed using

1 log- or logit-transformed frequencies. Classification performance was defined as the percentage
2 of donors that were assigned to the correct outcome cluster (i.e. deceased or survived). We
3 compared the abilities of different immune cell subsets to distinguish donor outcome by
4 repeating the clustering analysis on different combinations of trajectories. Greater classification
5 performance indicated increased power to identify donor outcomes. Clustering analyses were
6 conducted in *R* version 3.5.3 using the *kml3d* package, version 2.4.2, and the results were
7 visualized using the *ggplot2* package.

8

9 ***Processing of scRNA-seq Data***

10 We used kallisto v0.46.2 in “BUS” mode to pseudo-align the raw reads for each sample to a
11 merged human GRCh38 (Ensembl 93)/SARS-CoV-2 transcriptome (Bray et al., 2016; Kim et al.,
12 2020; Melsted et al., 2019a; Melsted et al., 2019b). To correct for index swapping, which can
13 occur on the Illumina NovaSeq 6000, we applied the algorithm of Griffiths *et al* (Griffiths et al.,
14 2018) to the equivalence classes obtained from kallisto pseudo-alignment. We generated a raw
15 count matrix from the swap-corrected BUS file using bustools v0.40.0(Melsted et al., 2019b),
16 filtered using the EmptyDrops algorithm (Lun et al., 2019), and removed all cells with
17 mitochondrial pseudo-alignment rates >20% or counts per gene greater than two standard
18 deviations above the mean for each sample.

19

20 ***scRNA-seq Cell Annotation***

21 We merged the scRNA-seq data from all of the airway samples and identified likely markers of
22 specific subpopulations using the previously described drop-out score method for finding genes
23 that are detected in fewer cells than expected given their expression level (Levitin et al., 2019;

1 Szabo et al., 2019). Next, we computed a cell-by-cell Spearman's rank correlation matrix using
2 these putative marker genes. Using this matrix, we constructed a k-nearest neighbor's graph
3 (k=20) as input for Louvain community detection as implemented in Phenograph (Levine et al.,
4 2015). To associate the resulting clusters with major cell populations in the airway, we examined
5 the statistical enrichment of the following marker genes in each cluster using the binomial test as
6 described in Shekhar *et al* (Shekhar et al., 2016): T cells (*CD3D*, *TRAC*, *TRBC1*, *TRBC2*, *TRDC*,
7 *TRGC1*, *TRGC2*), NK cells (*NCAMI*), myeloid cells (*CD14*, *FCGR3A*, *CD163*),
8 epithelial/club/goblet cells (*EPCAM*, *SCGB1A1*, *MUC5B*, *KRT78*), ionocytes (*CFTR*),
9 neutrophils (*CD16B*), plasma cells (*CD19*, *JCHAIN*), B cells (*CD19*, *MS4A1*), platelets
10 (*ITGA2B*, *PF4*), mast cells (*KIT*), dendritic cells (*FCERIA*, *CD1C*) and red blood cells (*HBA1*,
11 *HBA2*, *HBB*). We identified clusters as likely multiplets based on co-expression of multiple
12 marker sets (e.g. clusters enriched in both *CD14* and *CD3D* were marked as likely T cell /
13 myeloid cell multiplets). All of the cells in these clusters were marked as multiplets.

14 In the main text, we present focused analyses on myeloid cells, T cells, and
15 epithelial/club/goblet cells from the airway. To further refine our annotation, we re-clustered the
16 cells annotated as each of these three cell types separately using the methods described above.
17 We then re-analyzed the enrichment of cell type-specific markers in the resulting new clusters.
18 As expected, this focused re-analysis of each of these three major populations identified
19 additional putative multiplet clusters and cells that we likely mis-clustered in the initial merged
20 analysis. We conducted two rounds of re-clustering for each of these three major cell types to
21 produce a refined annotation. The top of Figure S2B shows a gene expression heatmap for key
22 markers genes in the merged airway data set colored by patient and cell type annotation. We
23 repeated the above procedure for the merged blood scRNA-seq profiles including a focused re-

1 clustering analysis of the cells that we originally annotated as myeloid and T cells for refinement.
2 The bottom of Figure S2B shows a gene expression heatmap for key markers genes in the
3 merged blood data set colored by patient and cell type annotation.

4

5 *scRNA-seq Visualization and Differential Expression Analysis*

6 We generated merged UMAP embeddings for the blood and airway T cells (Figure 2E, F) and
7 the blood and airway myeloid cells (Figure 4). In each case, we first identified genes that were
8 likely to contaminate either the myeloid or T cell profiles in either the blood or airway to avoid
9 including them in any of our downstream clustering, visualization, or differential expression
10 analysis. We conducted pairwise differential expression analysis between all of the cells
11 annotated as a cell type-of-interest (e.g. myeloid) and each group of cells with a different
12 annotation for the blood and airway from each patient separately. For each pairwise comparison,
13 we randomly subsampled the two groups of cells to the same cell number. Next, we randomly
14 subsampled the molecular counts for cells in the two groups such that they have the same
15 average number of counts per cell. We then generated a merged count matrix for the two groups
16 and applied the pooled normalization technique from the *scrn* package of Lun *et al* using the
17 *computeSumFactors* function (Lun et al., 2016). Finally, we conducted a gene-by-gene, non-
18 parametric differential expression analysis using the Mann-Whitney U-test as implemented with
19 the function *mannwhitneyu* from the Python package *scipy*. We corrected the resulting p-values
20 for false discovery using the Benjamini-Hochberg Procedure with the function *multipletests* from
21 the Python package *statsmodels*. Using the results of pairwise differential expression analysis,
22 we generated a blacklist of genes for a given cell type by taking any gene with at least 10-fold
23 enrichment in a different cell type with FDR<0.001 in at least two patients. We removed all

1 genes with any enrichment in the cell type-of-interest with $FDR < 0.001$ in any patient to avoid
2 eliminating patient-specific markers of the cell type-of-interest. The final blacklists for blood and
3 airway myeloid and T cells appear in Table S8.

4 For both myeloid and T cells, we took all of the cells in the data set that we had annotated
5 as each of these two cell types and used the drop-out score method described above to generate a
6 list of putative, highly variable marker genes for each patient. Next, we generated a merged
7 count matrix across all patients for a given cell type, which we normalized using the pooling
8 method of Lun *et al* as described above (Lun et al., 2016). We then generated a log-normalized
9 submatrix ($\log_2(\text{counts per million} + 1)$) containing the union of the marker gene sets identified
10 for each patient after removing genes on the airway and blood blacklists for the cell type-of-
11 interest. Using the *PCA* function in the Python package *scikit-learn*, we decomposed this
12 submatrix into its principal components. We used the 10 principal components with the largest
13 eigenvalues as input to the scRNA-seq batch correction algorithm Harmony (Korsunsky et al.,
14 2019). We made the function *HarmonyMatrix* aware of only the first 10 principal components
15 and the patient identifiers for each cell. Finally, we computed a two-dimensional embedding
16 using the Python implementation of the Uniform Manifold Approximation and Projection
17 (UMAP) algorithm (McInnes and Healy, 2018) and the Pearson correlation matrix of the
18 Harmony-corrected principal components. These embeddings appear in **Figures 2** and **4**.

19 For the differential expression analysis between blood and airway myeloid cells and
20 between blood and airway T cells, we used the Mann-Whitney U-test approach described above.
21 We removed genes on the blacklists described above for each cell type prior to subsampling,
22 normalization, and statistical testing. We also restricted this analysis to protein-coding genes and
23 removed all T cell receptor and immunoglobulin variable regions. We performed differential

1 expression separately on each pair of matched airway and blood samples (there are 12 patient
2 time points for which we have matched samples). Stringent criteria were used to select the
3 differentially expressed genes displayed in the heatmaps in **Figures 2** and **4**. For the myeloid cell
4 heatmap in **Figure 4**, a gene had to be differentially expressed with a fold-change of at least 4 in
5 either direction and $FDR < 0.001$ in at least 9 of the 12 matched sample pairs. For the T cell
6 heatmap in **Figure 2**, we applied the first two criteria, but required them in only 6 of the 12
7 matched sample pairs. Results for all of the pairwise differential expression analyses comparing
8 airway and blood T and myeloid cells can be found in Table S5 and Table S6, respectively.

9

10 *Analysis and visualization of Cytokine data*

11 Cytokine expression data from early and late time points was \log_{10} normalized and visualized as
12 box plots overlaid with individual data points. The \log_{10} normalized data was averaged across
13 both the time points and used to generate heatmaps for cytokine expression across individual
14 donor samples. Non-log transformed cytokine expression data from both time points was
15 averaged for airway and plasma from each donor and used for paired-site analysis. Graphs were
16 generated using the Python *matplotlib* and *seaborn* libraries (Hunter, 2007). All code for analysis
17 of data and generation of figures will be hosted on GitHub.

18

19 *Lung tissue imaging analysis*

20 Tissue segmentation was performed using inForm software on 10-30 representative fields
21 (Version 2.3, PerkinElmer). Immune cell constituents within each tissue segment were defined
22 by the DAPI nuclear counterstain to define the nucleus of each cell, with each associated
23 membrane detected via presence of a specific stain (CD3, CD19, CD4, GzmB and/or CD163).

1 Cell segmentation was adjusted as previously described to accurately locate all cells and
2 minimize nuclear hypersegmentation and hyposegmentation (Weisberg et al., 2019). Cells were
3 then phenotyped by training the phenotyping algorithm of inForm software, identifying:
4 macrophage (CD163⁺ magenta cells), T cells (CD4⁺ cyan cells and CD8⁺ orange cells), B cells
5 (CD19⁺ yellow cells). The cell segmentation data summary provided densities and numbers of
6 each cell type in the lung tissue segments and the full cell segmentation data file provided the X
7 and Y coordinates of each phenotyped cell.

8

9 *Statistical Analysis*

10 Differences in mean between two sample groups were compared using Mann-Whitney U test,
11 multiple group comparisons were done using ANOVA followed by Tukey's HSD post-test and
12 paired t-test for any paired data custom scripts based on Python *sciPy* library (Jones et al., 2001).
13 *P*-values below 0.05 were considered as statistically significant. For all figures *** = *p*-value <
14 0.001, ** = *p*-value < 0.01, and * = *p*-value < 0.05.

15

16 **DATA AND CODE AVAILABILITY**

17 The scRNA-seq data for each sample including count matrices, normalized counts, metadata, cell
18 annotations, and UMAP embeddings are available on the COVID-19 Cell Atlas along with
19 interactive visualizations (<https://www.covid19cellatlas.org/index.patient.html>). The scRNA-seq
20 data analysis code is available at www.github.com/simslab/cluster_diffex2018.

21

22

23

24

1 **Supplementary Tables**

2 **Table S1.** Clinical information for COVID-19 patients in this study.

3 **Table S2.** Assays performed on the samples from individual COVID-19 patients.

4 **Table S3.** Summary of sample details for scRNA-seq analysis.

5 **Table S4.** PCA loadings of markers for PC1 and PC2.

6 **Table S5.** Differential gene expression by T cells in airway versus blood for each sample by
7 scRNA-seq.

8 **Table S6.** Differential gene expression by myeloid cells in airway versus blood for each sample
9 by scRNA-seq.

10 **Table S7.** Deceased donors for control airway and COVID-19 lung autopsy samples

11 **Table S8.** Blacklisted genes for a given cell type for the scRNAseq analysis.

12

1 REFERENCES

- 2 Aggarwal, N.R., King, L.S., and D'Alessio, F.R. (2014). Diverse macrophage populations
3 mediate acute lung inflammation and resolution. *Am J Physiol Lung Cell Mol Physiol* 306,
4 L709-725.
- 5
6 Allen, A.C., Wilk, M.M., Misiak, A., Borkner, L., Murphy, D., and Mills, K.H.G. (2018).
7 Sustained protective immunity against *Bordetella pertussis* nasal colonization by intranasal
8 immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells.
9 *Mucosal Immunol* 11, 1763-1776.
- 10
11 Bharat, A., Bhorade, S.M., Morales-Nebreda, L., McQuattie-Pimentel, A.C., Soberanes, S.,
12 Ridge, K., DeCamp, M.M., Mestan, K.K., Perlman, H., Budinger, G.R., and Misharin, A.V.
13 (2016). Flow Cytometry Reveals Similarities Between Lung Macrophages in Humans and Mice.
14 *Am J Respir Cell Mol Biol* 54, 147-149.
- 15
16 Bray, N.L., Pimentel, H., Melsted, P., and Pachter, L. (2016). Near-optimal probabilistic RNA-
17 seq quantification. *Nature biotechnology* 34, 525-527.
- 18
19 Buechler, C., Ritter, M., Orso, E., Langmann, T., Klucken, J., and Schmitz, G. (2000).
20 Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by
21 pro- and antiinflammatory stimuli. *J Leukoc Biol* 67, 97-103.
- 22
23 Carpenter, D.J., Granot, T., Matsuoka, N., Senda, T., Kumar, B.V., Thome, J.J.C., Gordon, C.L.,
24 Miron, M., Weiner, J., Connors, T., Lerner, H., Friedman, A., Kato, T., Griesemer, A.D., and
25 Farber, D.L. (2018). Human immunology studies using organ donors: Impact of clinical
26 variations on immune parameters in tissues and circulation. *Am J Transplant* 18, 74-88.
- 27
28 Chau, A.S., Weber, A.G., Maria, N.I., Narain, S., Liu, A., Hajizadeh, N., Malhotra, P., Bloom,
29 O., Marder, G., and Kaplan, B. (2020). The Longitudinal Immune Response to Coronavirus
30 Disease 2019: Chasing the Cytokine Storm. *Arthritis Rheumatol*.
- 31
32 Choi, Y.S., Gullicksrud, J.A., Xing, S., Zeng, Z., Shan, Q., Li, F., Love, P.E., Peng, W., Xue,
33 H.H., and Crotty, S. (2015). LEF-1 and TCF-1 orchestrate T(FH) differentiation by regulating
34 differentiation circuits upstream of the transcriptional repressor Bcl6. *Nat Immunol* 16, 980-990.
- 35
36 Connors, T.J., Baird, J.S., Yopes, M.C., Zens, K.D., Pethe, K., Ravindranath, T.M., Ho, S.H.,
37 and Farber, D.L. (2018). Developmental Regulation of Effector and Resident Memory T Cell
38 Generation during Pediatric Viral Respiratory Tract Infection. *J Immunol* 201, 432-439.

39

- 1 Connors, T.J., Ravindranath, T.M., Bickham, K.L., Gordon, C.L., Zhang, F., Levin, B., Baird,
2 J.S., and Farber, D.L. (2016). Airway CD8(+) T Cells Are Associated with Lung Injury during
3 Infant Viral Respiratory Tract Infection. *Am J Respir Cell Mol Biol* 54, 822-830.
- 4
- 5 Copaesca, A., Smibert, O., Gibson, A., Phillips, E.J., and Trubiano, J.A. (2020). The role of IL-6
6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection. *J Allergy Clin*
7 *Immunol* 146, 518-534 e511.
- 8
- 9 Cummings, M.J., Baldwin, M.R., Abrams, D., Jacobson, S.D., Meyer, B.J., Balough, E.M.,
10 Aaron, J.G., Claassen, J., Rabbani, L.E., Hastie, J., Hochman, B.R., Salazar-Schicchi, J., Yip,
11 N.H., Brodie, D., and O'Donnell, M.R. (2020). Epidemiology, clinical course, and outcomes of
12 critically ill adults with COVID-19 in New York City: a prospective cohort study. *Lancet* 395,
13 1763-1770.
- 14
- 15 Damiani, S., Fiorentino, M., De Palma, A., Foschini, M.P., Lazzarotto, T., Gabrielli, L., Viale,
16 P.L., Attard, L., Riefolo, M., and D'Errico, A. (2020). Pathological Post Mortem Findings in
17 Lungs Infected With Sars-Cov 2. *J Pathol*.
- 18
- 19 Darrah, P.A., Zeppa, J.J., Maiello, P., Hackney, J.A., Wadsworth, M.H., 2nd, Hughes, T.K.,
20 Pokkali, S., Swanson, P.A., 2nd, Grant, N.L., Rodgers, M.A., *et al.* (2020). Prevention of
21 tuberculosis in macaques after intravenous BCG immunization. *Nature* 577, 95-102.
- 22
- 23 Davies, N.G., Klepac, P., Liu, Y., Prem, K., Jit, M., group, C.C.-w., and Eggo, R.M. (2020).
24 Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med* 26,
25 1205-1211.
- 26
- 27 De Michele, S., Sun, Y., Yilmaz, M.M., Katsyv, I., Salvatore, M., Dzierba, A.L., Marboe, C.C.,
28 Brodie, D., Patel, N.M., Garcia, C.K., and Saqi, A. (2020). Forty Postmortem Examinations in
29 COVID-19 Patients. *Am J Clin Pathol*.
- 30
- 31 Della-Torre, E., Campochiaro, C., Cavalli, G., De Luca, G., Napolitano, A., La Marca, S.,
32 Boffini, N., Da Prat, V., Di Terlizzi, G., Lanzillotta, M., *et al.* (2020). Interleukin-6 blockade
33 with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label
34 cohort study. *Ann Rheum Dis* 79, 1277-1285.
- 35
- 36 Dogra, P., Rancan, C., Ma, W., Toth, M., Senda, T., Carpenter, D.J., Kubota, M., Matsumoto, R.,
37 Thapa, P., Szabo, P.A., Li Poon, M.M., Li, J., Arakawa-Hoyt, J., Shen, Y., Fong, L., Lanier,
38 L.L., and Farber, D.L. (2020). Tissue Determinants of Human NK Cell Development, Function,
39 and Residence. *Cell* 180, 749-763 e713.

40

- 1 Farhadian, S., Glick, L.R., Vogels, C.B.F., Thomas, J., Chiarella, J., Casanovas-Massana, A.,
2 Zhou, J., Odio, C., Vijayakumar, P., Geng, B., *et al.* (2020). Acute encephalopathy with elevated
3 CSF inflammatory markers as the initial presentation of COVID-19. *BMC Neurol* 20, 248.
- 4
5 Furlow, B. (2020). COVACTA trial raises questions about tocilizumab's benefit in COVID-19.
6 *Lancet Rheumatol.*
- 7
8 Gartrell, R.D., Marks, D.K., Hart, T.D., Li, G., Davari, D.R., Wu, A., Blake, Z., Lu, Y., Askin,
9 K.N., Monod, A., *et al.* (2018). Quantitative Analysis of Immune Infiltrates in Primary
10 Melanoma. *Cancer Immunol Res* 6, 481-493.
- 11
12 Griffiths, J.A., Richard, A.C., Bach, K., Lun, A.T.L., and Marioni, J.C. (2018). Detection and
13 removal of barcode swapping in single-cell RNA-seq data. *Nature communications* 9, 2667.
- 14
15 Grifoni, A., Weiskopf, D., Ramirez, S.I., Mateus, J., Dan, J.M., Moderbacher, C.R., Rawlings,
16 S.A., Sutherland, A., Premkumar, L., Jodi, R.S., *et al.* (2020). Targets of T Cell Responses to
17 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell*
18 181, 1489-1501 e1415.
- 19
20 Hadjadj, J., Yatim, N., Barnabei, L., Corneau, A., Boussier, J., Smith, N., Pere, H., Charbit, B.,
21 Bondet, V., Chenevier-Gobeaux, C., *et al.* (2020). Impaired type I interferon activity and
22 inflammatory responses in severe COVID-19 patients. *Science* 369, 718-724.
- 23
24 Hassan, A.O., Kafai, N.M., Dmitriev, I.P., Fox, J.M., Smith, B.K., Harvey, I.B., Chen, R.E.,
25 Winkler, E.S., Wessel, A.W., Case, J.B., *et al.* (2020). A Single-Dose Intranasal ChAd Vaccine
26 Protects Upper and Lower Respiratory Tracts against SARS-CoV-2. *Cell* 183, 169-184 e113.
- 27
28 Hendrix, A.Y., and Kheradmand, F. (2017). The Role of Matrix Metalloproteinases in
29 Development, Repair, and Destruction of the Lungs. *Prog Mol Biol Transl Sci* 148, 1-29.
- 30
31 Hunter, J.D. (2007). Matplotlib: A 2D graphics environment. *Computing In Science and*
32 *Engineering* 9, 90-95.
- 33
34 Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M.S., Lichty, B.D., and Xing, Z. (2020).
35 Immunological considerations for COVID-19 vaccine strategies. *Nat Rev Immunol.*
- 36
37 Jones, E., Oliphant, T., and Peterson, P. (2001). *SciPy: Open source scientific tools for Python.*
- 38

- 1 Kapellos, T.S., Bonaguro, L., Gemund, I., Reusch, N., Saglam, A., Hinkley, E.R., and Schultze,
2 J.L. (2019). Human Monocyte Subsets and Phenotypes in Major Chronic Inflammatory Diseases.
3 *Front Immunol* *10*, 2035.
- 4
- 5 Khemani, R.G., Smith, L.S., Zimmerman, J.J., Erickson, S., and Pediatric Acute Lung Injury
6 Consensus Conference, G. (2015). Pediatric acute respiratory distress syndrome: definition,
7 incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus
8 Conference. *Pediatr Crit Care Med* *16*, S23-40.
- 9
- 10 Kim, D., Lee, J.Y., Yang, J.S., Kim, J.W., Kim, V.N., and Chang, H. (2020). The Architecture of
11 SARS-CoV-2 Transcriptome. *Cell* *181*, 914-921 e910.
- 12
- 13 Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner,
14 M., Loh, P.-r., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-
15 cell data with Harmony. *Nature methods*, 1-8.
- 16
- 17 Kumar, B.V., Connors, T.J., and Farber, D.L. (2018). Human T Cell Development, Localization,
18 and Function throughout Life. *Immunity* *48*, 202-213.
- 19
- 20 Kumar, B.V., Ma, W., Miron, M., Granot, T., Guyer, R.S., Carpenter, D.J., Senda, T., Sun, X.,
21 Ho, S.H., Lerner, H., Friedman, A.L., Shen, Y., and Farber, D.L. (2017). Human Tissue-Resident
22 Memory T Cells Are Defined by Core Transcriptional and Functional Signatures in Lymphoid
23 and Mucosal Sites. *Cell Rep* *20*, 2921-2934.
- 24
- 25 Kuri-Cervantes, L., Pampera, M.B., Meng, W., Rosenfeld, A.M., Ittner, C.A.G., Weisman, A.R.,
26 Agyekum, R.S., Mathew, D., Baxter, A.E., Vella, L.A., *et al.* (2020). Comprehensive mapping of
27 immune perturbations associated with severe COVID-19. *Sci Immunol* *5*.
- 28
- 29 Laing, A.G., Lorenc, A., Del Molino Del Barrio, I., Das, A., Fish, M., Monin, L., Munoz-Ruiz,
30 M., McKenzie, D.R., Hayday, T.S., Francos-Quijorna, I., *et al.* (2020). A dynamic COVID-19
31 immune signature includes associations with poor prognosis. *Nat Med*.
- 32
- 33 Levine, J.H., Simonds, E.F., Bendall, S.C., Davis, K.L., Amir el, A.D., Tadmor, M.D., Litvin,
34 O., Fienberg, H.G., Jager, A., Zunder, E.R., Finck, R., Gedman, A.L., Radtke, I., Downing, J.R.,
35 Pe'er, D., and Nolan, G.P. (2015). Data-Driven Phenotypic Dissection of AML Reveals
36 Progenitor-like Cells that Correlate with Prognosis. *Cell* *162*, 184-197.
- 37
- 38 Levitin, H.M., Yuan, J., Cheng, Y.L., Ruiz, F.J.R., Bush, E.C., Bruce, J.N., Canoll, P., Iavarone,
39 A., Lasorella, A., Blei, D.M., and Sims, P.A. (2019). De novo Gene Signature Identification

- 1 from Single-Cell RNA-seq with Hierarchical Poisson Factorization. *Molecular Systems Biology*
2 *15*.
- 3
- 4 Li, Z., Ding, Q., and Zhang, W. (2011). A Comparative Study of Different Distances for
5 Similarity Estimation. . In *Intelligent Computing and Information Science ICICIS 2011*
6 *Communications in Computer and Information Science*, R. Chen, ed. (Berlin: Springer).
- 7
- 8 Liao, M., Liu, Y., Yuan, J., Wen, Y., Xu, G., Zhao, J., Cheng, L., Li, J., Wang, X., Wang, F.,
9 Liu, L., Amit, I., Zhang, S., and Zhang, Z. (2020). Single-cell landscape of bronchoalveolar
10 immune cells in patients with COVID-19. *Nat Med* *26*, 842-844.
- 11
- 12 Lin, K.L., Suzuki, Y., Nakano, H., Ramsburg, E., and Gunn, M.D. (2008). CCR2+ monocyte-
13 derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune
14 pathology and mortality. *J Immunol* *180*, 2562-2572.
- 15
- 16 Lin, K.L., Sweeney, S., Kang, B.D., Ramsburg, E., and Gunn, M.D. (2011). CCR2-antagonist
17 prophylaxis reduces pulmonary immune pathology and markedly improves survival during
18 influenza infection. *J Immunol* *186*, 508-515.
- 19
- 20 Long, Q.X., Liu, B.Z., Deng, H.J., Wu, G.C., Deng, K., Chen, Y.K., Liao, P., Qiu, J.F., Lin, Y.,
21 Cai, X.F., *et al.* (2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat*
22 *Med* *26*, 845-848.
- 23
- 24 Lucas, C., Wong, P., Klein, J., Castro, T.B.R., Silva, J., Sundaram, M., Ellingson, M.K., Mao, T.,
25 Oh, J.E., Israelow, B., *et al.* (2020). Longitudinal analyses reveal immunological misfiring in
26 severe COVID-19. *Nature* *584*, 463-469.
- 27
- 28 Lun, A.T., Bach, K., and Marioni, J.C. (2016). Pooling across cells to normalize single-cell RNA
29 sequencing data with many zero counts. *Genome biology* *17*, 75.
- 30
- 31 Lun, A.T., Riesenfeld, S., Andrews, T., Gomes, T., and Marioni, J.C. (2019). EmptyDrops:
32 distinguishing cells from empty droplets in droplet-based single-cell RNA sequencing data.
33 *Genome biology* *20*, 1-9.
- 34
- 35 Mackay, L.K., Minnich, M., Kragten, N.A., Liao, Y., Nota, B., Seillet, C., Zaid, A., Man, K.,
36 Preston, S., Freestone, D., *et al.* (2016). Hobit and Blimp1 instruct a universal transcriptional
37 program of tissue residency in lymphocytes. *Science* *352*, 459-463.

38

- 1 Masopust, D., and Soerens, A.G. (2019). Tissue-Resident T Cells and Other Resident
2 Leukocytes. *Annu Rev Immunol* 37, 521-546.
- 3
4 Mathew, D., Giles, J.R., Baxter, A.E., Oldridge, D.A., Greenplate, A.R., Wu, J.E., Alanio, C.,
5 Kuri-Cervantes, L., Pampena, M.B., D'Andrea, K., *et al.* (2020). Deep immune profiling of
6 COVID-19 patients reveals distinct immunotypes with therapeutic implications. *Science* 369.
- 7
8 Matics, T.J., and Sanchez-Pinto, L.N. (2017). Adaptation and Validation of a Pediatric
9 Sequential Organ Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in
10 Critically Ill Children. *JAMA Pediatr* 171, e172352.
- 11
12 McInnes, L., and Healy, J. (2018). UMAP: Uniform Manifold Approximation and Projection for
13 Dimension Reduction. arXiv, arXiv:1802.03426.
- 14
15 McInnes, L., Healy, J., Saul, N., and Grossberger, L. (2018). UMAP: Uniform Manifold
16 Approximation and Projection. *J Open Source Software* 3, 861.
- 17
18 Melsted, P., Boeshaghi, A.S., Gao, F., Beltrame, E., Lu, L., Hjorleifsson, K.E., Gehring, J., and
19 Pachter, L. (2019a). Modular and efficient pre-processing of single-cell RNA-seq. bioRxiv,
20 673285.
- 21
22 Melsted, P., Ntranos, V., and Pachter, L. (2019b). The barcode, UMI, set format and BUStools.
23 *Bioinformatics (Oxford, England)* 35, 4472-4473.
- 24
25 Moderbacher, C.R., Ramirez, S.I., Dan, J.M., Grifoni, A., Hastie, K.M., Weiskopf, D., Belanger,
26 S., Abbott, R.K., Kim, C., Choi, J., *et al.* (2020). Antigen-specific adaptive immunity to SARS-
27 CoV-2 in acute COVID-19 and
28 associations with age and disease severity. *Cell* <https://doi.org/10.1016/j.cell.2020.09.038>.
- 29
30 Morrell, E.D., Bhatraju, P.K., Mikacenic, C.R., Radella, F., 2nd, Manicone, A.M., Stapleton,
31 R.D., Wurfel, M.M., and Gharib, S.A. (2019). Alveolar Macrophage Transcriptional Programs
32 Are Associated with Outcomes in Acute Respiratory Distress Syndrome. *Am J Respir Crit Care*
33 *Med* 200, 732-741.
- 34
35 Ni, L., Ye, F., Cheng, M.L., Feng, Y., Deng, Y.Q., Zhao, H., Wei, P., Ge, J., Gou, M., Li, X., *et*
36 *al.* (2020). Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19
37 Convalescent Individuals. *Immunity* 52, 971-977 e973.

38

- 1 Paik, D., and Farber, D.L. (2020). Influenza infection fortifies local lymph nodes to promote
2 lung resident heterosubtypic immunity. *J Exp Med* *in Revision*.
- 3
- 4 Pedregosa, F., Varoquaux, G., Gramfort, A., Michel, V., Thirion, B., Grisel, O., Blondel, M.,
5 Prettenhofer, P., Weiss, R., Dubourg, V., Vanderplas, J., Passos, A., Cournapeau, D., Brucher,
6 M., Perrot, M., and Duchesnay, E. (2011). Scikit-learn: Machine Learning in Python. *J Mach*
7 *Learn Res* *12*, 2825-2830.
- 8
- 9 Ranieri, V.M., Rubenfeld, G.D., Thompson, B.T., Ferguson, N.D., Caldwell, E., Fan, E.,
10 Camporota, L., and Slutsky, A.S. (2012). Acute respiratory distress syndrome: the Berlin
11 Definition. *JAMA* *307*, 2526-2533.
- 12
- 13 Schulte-Schrepping, J., Reusch, N., Paclik, D., Bassler, K., Schlickeiser, S., Zhang, B., Kramer,
14 B., Krammer, T., Brumhard, S., Bonaguro, L., *et al.* (2020). Severe COVID-19 Is Marked by a
15 Dysregulated Myeloid Cell Compartment. *Cell* *182*, 1419-1440 e1423.
- 16
- 17 Schultze, J.L., Mass, E., and Schlitzer, A. (2019). Emerging Principles in Myelopoiesis at
18 Homeostasis and during Infection and Inflammation. *Immunity* *50*, 288-301.
- 19
- 20 Shekhar, K., Lapan, S.W., Whitney, I.E., Tran, N.M., Macosko, E.Z., Kowalczyk, M., Adiconis,
21 X., Levin, J.Z., Nemesh, J., Goldman, M., McCarroll, S.A., Cepko, C.L., Regev, A., and Sanes,
22 J.R. (2016). Comprehensive Classification of Retinal Bipolar Neurons by Single-Cell
23 Transcriptomics. *Cell* *166*, 1308-1323 e1330.
- 24
- 25 Shi, C., Jia, T., Mendez-Ferrer, S., Hohl, T.M., Serbina, N.V., Lipuma, L., Leiner, I., Li, M.O.,
26 Frenette, P.S., and Pamer, E.G. (2011). Bone marrow mesenchymal stem and progenitor cells
27 induce monocyte emigration in response to circulating toll-like receptor ligands. *Immunity* *34*,
28 590-601.
- 29
- 30 Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.G., Dubuisson, A., Derosa, L., Almire, C.,
31 Henon, C., Kosmider, O., Droin, N., *et al.* (2020). Elevated Calprotectin and Abnormal Myeloid
32 Cell Subsets Discriminate Severe from Mild COVID-19. *Cell* *182*, 1401-1418 e1418.
- 33
- 34 Singer, M., Deutschman, C.S., Seymour, C.W., Shankar-Hari, M., Annane, D., Bauer, M.,
35 Bellomo, R., Bernard, G.R., Chiche, J.D., Coopersmith, C.M., Hotchkiss, R.S., Levy, M.M.,
36 Marshall, J.C., Martin, G.S., Opal, S.M., Rubenfeld, G.D., van der Poll, T., Vincent, J.L., and
37 Angus, D.C. (2016). The Third International Consensus Definitions for Sepsis and Septic Shock
38 (Sepsis-3). *JAMA* *315*, 801-810.

39

- 1 Snyder, M.E., Finlayson, M.O., Connors, T.J., Dogra, P., Senda, T., Bush, E., Carpenter, D.,
2 Marboe, C., Benvenuto, L., Shah, L., *et al.* (2019). Generation and persistence of human tissue-
3 resident memory T cells in lung transplantation. *Sci Immunol* *4*, eaav5581.
- 4
- 5 Szabo, P.A., Levitin, H.M., Miron, M., Snyder, M.E., Senda, T., Yuan, J., Cheng, Y.L., Bush,
6 E.C., Dogra, P., Thapa, P., Farber, D.L., and Sims, P.A. (2019). Single-cell transcriptomics of
7 human T cells reveals tissue and activation signatures in health and disease. *Nat Commun* *10*,
8 4706.
- 9
- 10 Takahashi, T., Ellingson, M.K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao, T.,
11 Oh, J.E., Tokuyama, M., *et al.* (2020). Sex differences in immune responses that underlie
12 COVID-19 disease outcomes. *Nature*.
- 13
- 14 Teijaro, J.R., Turner, D., Pham, Q., Wherry, E.J., Lefrancois, L., and Farber, D.L. (2011a).
15 Cutting edge: tissue-retentive lung memory CD4 T cells mediate optimal protection to
16 respiratory virus infection. *J Immunol* *187*, 5510-5514.
- 17
- 18 Teijaro, J.R., Walsh, K.B., Cahalan, S., Fremgen, D.M., Roberts, E., Scott, F., Martinborough,
19 E., Peach, R., Oldstone, M.B., and Rosen, H. (2011b). Endothelial cells are central orchestrators
20 of cytokine amplification during influenza virus infection. *Cell* *146*, 980-991.
- 21
- 22 Thieme, C.J., Anft, M., Paniskaki, K., Blazquez-Navarro, A., Doevelaar, A., Seibert, F.S.,
23 Hoelzer, B., Konik, M.J., Brenner, T., Tempfer, C., *et al.* (2020). Robust T cell response towards
24 spike, membrane, and nucleocapsid SARS-CoV-2 proteins is not associated with recovery in
25 critical COVID-19 patients. *Cell Rep Med*, 100092.
- 26
- 27 Turner, D.L., Bickham, K.L., Thome, J.J., Kim, C.Y., D'Ovidio, F., Wherry, E.J., and Farber,
28 D.L. (2014). Lung niches for the generation and maintenance of tissue-resident memory T cells.
29 *Mucosal Immunol* *7*, 501-510.
- 30
- 31 Turner, D.L., and Farber, D.L. (2014). Mucosal resident memory CD4 T cells in protection and
32 immunopathology. *Front Immunol* *5*, 331.
- 33
- 34 van der Walt, S., Colbert, S.C., and Varoquaux, G. (2011). The NumPy Array: A Structure for
35 Efficient Numerical Computation. *Computing in Science & Engineering* *13*, 22-30.
- 36
- 37 Vasilevskis, E.E., Pandharipande, P.P., Graves, A.J., Shintani, A., Tsuruta, R., Ely, E.W., and
38 Girard, T.D. (2016). Validity of a Modified Sequential Organ Failure Assessment Score Using
39 the Richmond Agitation-Sedation Scale. *Crit Care Med* *44*, 138-146.


- 1
2 Venet, F., Demaret, J., Gossez, M., and Monneret, G. (2020). Myeloid cells in sepsis-acquired
3 immunodeficiency. *Ann N Y Acad Sci*.
- 4
5 Veras, F.P., Pontelli, M.C., Silva, C.M., Toller-Kawahisa, J.E., de Lima, M., Nascimento, D.C.,
6 Schneider, A.H., Caetite, D., Tavares, L.A., Paiva, I.M., *et al.* (2020). SARS-CoV-2-triggered
7 neutrophil extracellular traps mediate COVID-19 pathology. *J Exp Med* 217.
- 8
9 Weisberg, S.P., Carpenter, D.J., Chait, M., Dogra, P., Gartrell-Corrado, R.D., Chen, A.X.,
10 Campbell, S., Liu, W., Saraf, P., Snyder, M.E., Kubota, M., Danzl, N.M., Schroppe, B.A.,
11 Rabadan, R., Saenger, Y., Chen, X., and Farber, D.L. (2019). Tissue-Resident Memory T Cells
12 Mediate Immune Homeostasis in the Human Pancreas through the PD-1/PD-L1 Pathway. *Cell*
13 *Rep* 29, 3916-3932 e3915.
- 14
15 Weisberg, S.P., Connors, T., Zhu, Y., Baldwin, M., Lin, W.H., Wontakal, S., Szabo, P.A., Wells,
16 S.B., Dogra, P., Gray, J.I., *et al.* (2020). Antibody responses to SARS-CoV2 are distinct in
17 children with MIS-C compared to adults with COVID-19. medRxiv.
- 18
19 Weisel, N.M., Weisel, F.J., Farber, D.L., Borghesi, L.A., Shen, Y., Ma, W., Luning Prak, N.T.,
20 and Shlomchik, M.J. (2020). Comprehensive analysis of B cell compartments across the human
21 body reveals novel subsets and a gut resident memory phenotype. *Blood In Press*.
- 22
23 Weiskopf, D., Schmitz, K.S., Raadsen, M.P., Grifoni, A., Okba, N.M.A., Endeman, H., van den
24 Akker, J.P.C., Molenkamp, R., Koopmans, M.P.G., van Gorp, E.C.M., Haagmans, B.L., de
25 Swart, R.L., Sette, A., and de Vries, R.D. (2020). Phenotype and kinetics of SARS-CoV-2-
26 specific T cells in COVID-19 patients with acute respiratory distress syndrome. *Sci Immunol* 5.
- 27
28 Wu, T., Hu, Y., Lee, Y.T., Bouchard, K.R., Benechet, A., Khanna, K., and Cauley, L.S. (2014).
29 Lung-resident memory CD8 T cells (TRM) are indispensable for optimal cross-protection
30 against pulmonary virus infection. *J Leukoc Biol* 95, 215-224.
- 31
32 Wu, Z., and McGoogan, J.M. (2020). Characteristics of and Important Lessons From the
33 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314
34 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*.
- 35
36 Yoo, J.K., Kim, T.S., Hufford, M.M., and Braciale, T.J. (2013). Viral infection of the lung: host
37 response and sequelae. *J Allergy Clin Immunol* 132, 1263-1276.
- 38

1 Zens, K.D., Chen, J.-K., and Farber, D.L. (2016). Vaccine-Generated Lung Tissue-Resident
2 Memory T cells Provide Heterosubtypic Protection to Influenza Infection. *J Clin Invest Insight* 1
3 e85832.



4
5 Zhao, J., Zhao, J., Mangalam, A.K., Channappanavar, R., Fett, C., Meyerholz, D.K.,
6 Agnihothram, S., Baric, R.S., David, C.S., and Perlman, S. (2016). Airway Memory CD4(+) T
7 Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. *Immunity* 44,
8 1379-1391.

9


10




A




C




D








E




F









A




B




C






A



B



C

